Deepak L. Bhatt, MD, MPH - Department of Medicine

Deepak L. Bhatt, MD, MPH

View Physician Profile

Senior Physician, Brigham and Women's Hospital
Professor of Medicine, Harvard Medical School

Brigham and Women's Hospital
Department of Medicine
Cardiovascular
75 Francis Street
Boston, MA 02115

Research Location: Peter Bent Brigham

Education:	Harvard School of Public Health, 2008, MPH Cornell University Medical College, 1993, MD Massachusetts Institute of Technology, 1989, BS

Honors/Awards:	Cardiovascular Fellows’ Visiting Professor, Mayo Clinic, Rochester, Minnesota, 2010 Anandi L. Sharma Visiting Professorship, Mount Sinai School of Medicine, New York, 2009 Simon Dack Award for Outstanding Scholarship, American College of Cardiology, 2009 Distinguished Faculty Award for Excellence in Research Mentorship, Cleveland Clinic, 2008 Greenfield Visiting Professor, Duke University, 2012 Elected into Association of University Cardiologists, 2010 Best Doctors in America, 2005-2012

Publications (Pulled from Harvard Catalyst Profiles): 1. Bhatt DL, Stone GW, Mahaffey KW, Gibson CM, Steg PG, Hamm CW, Price MJ, Leonardi S, Gallup D, Bramucci E, Radke PW, Widimský P, Tousek F, Tauth J, Spriggs D, McLaurin BT, Angiolillo DJ, Généreux P, Liu T, Prats J, Todd M, Skerjanec S, White HD, Harrington RA. Effect of platelet inhibition with cangrelor during PCI on ischemic events. N Engl J Med. 2013 Apr 4; 368(14):1303-13. 2. Bhatt DL. Timely PCI for STEMI--still the treatment of choice. N Engl J Med. 2013 Apr 11; 368(15):1446-7. 3. Clarke JC, Aragam JR, Bhatt DL, Brown JD, Ferrazzani S, Pietro DA, Maron BA. An unusual cause of dyspnea diagnosed late in life: severe pulmonary hypertension resulting from isolated anomalous pulmonary venous connection. Circ Cardiovasc Imaging. 2013 Mar 1; 6(2):349-51. 4. Udell JA, Steg PG, Bhatt DL. Impact of loneliness and living alone-reply. JAMA Intern Med. 2013 Feb 25; 173(4):322-3. 5. Bui AL, Grau-Sepulveda MV, Hernandez AF, Peterson ED, Yancy CW, Bhatt DL, Fonarow GC. Admission heart rate and in-hospital outcomes in patients hospitalized for heart failure in sinus rhythm and in atrial fibrillation. Am Heart J. 2013 Apr; 165(4):567-574.e6. 6. Bangalore S, Fusaro M, Amoroso N, Attubato MJ, Feit F, Slater J, Kumar S, Bhatt DL. Response to letter regarding article, “Short- and long-term outcomes with drug-eluting and bare-metal coronary stents: a mixed-treatment comparison Analysis of 117,762 patient-years of follow-up from randomized trials”. Circulation. 2013 Feb 12; 127(6):e447. 7. Bangalore S, Steg PG, Bhatt DL. ß-Blocker use for patients with or at risk for coronary artery disease--reply. JAMA. 2013 Feb 6; 309(5):439-40. 8. Bhatt DL. Pushing the boundaries of renal denervation for resistant hypertension. Catheter Cardiovasc Interv. 2013 Feb; 81(2):340-1. 9. Huo Y, Choy JS, Wischgoll T, Luo T, Teague SD, Bhatt DL, Kassab GS. Computed tomography-based diagnosis of diffuse compensatory enlargement of coronary arteries using scaling power laws. J R Soc Interface. 2013; 10(81):20121015. 10. Frelinger AL, Bhatt DL, Lee RD, Mulford DJ, Wu J, Nudurupati S, Nigam A, Lampa M, Brooks JK, Barnard MR, Michelson AD. Clopidogrel Pharmacokinetics and Pharmacodynamics Vary Widely Despite Exclusion or Control of Polymorphisms (CYP2C19, ABCB1, PON1), Noncompliance, Diet, Smoking, Co-Medications (Including Proton Pump Inhibitors), and Pre-Existent Variability in Platelet Function. J Am Coll Cardiol. 2013 Feb 26; 61(8):872-9. show all 11. Agrawal K, Bhatt DL. Antiplatelet therapy: Does prasugrel or ticagrelor suffice in patients with STEMI? Nat Rev Cardiol. 2013 Mar; 10(3):121-2. 12. Sirimarco G, Amarenco P, Labreuche J, Touboul PJ, Alberts M, Goto S, Rother J, Mas JL, Bhatt DL, Steg PG. Carotid atherosclerosis and risk of subsequent coronary event in outpatients with atherothrombosis. Stroke. 2013 Feb; 44(2):373-9. 13. Ganesh SK, Tragante V, Guo W, Guo Y, Lanktree MB, Smith EN, Johnson T, Castillo BA, Barnard J, Baumert J, Chang YP, Elbers CC, Farrall M, Fischer ME, Franceschini N, Gaunt TR, Gho JM, Gieger C, Gong Y, Isaacs A, Kleber ME, Mateo Leach I, McDonough CW, Meijs MF, Mellander O, Molony CM, Nolte IM, Padmanabhan S, Price TS, Rajagopalan R, Shaffer J, Shah S, Shen H, Soranzo N, van der Most PJ, Van Iperen EP, Van Setten JA, Vonk JM, Zhang L, Beitelshees AL, Berenson GS, Bhatt DL, Boer JM, Boerwinkle E, Burkley B, Burt A, Chakravarti A, Chen W, Cooper-Dehoff RM, Curtis SP, Dreisbach A, Duggan D, Ehret GB, Fabsitz RR, Fornage M, Fox E, Furlong CE, Gansevoort RT, Hofker MH, Hovingh GK, Kirkland SA, Kottke-Marchant K, Kutlar A, Lacroix AZ, Langaee TY, Li YR, Lin H, Liu K, Maiwald S, Malik R, Murugesan G, Newton-Cheh C, O'Connell JR, Onland-Moret NC, Ouwehand WH, Palmas W, Penninx BW, Pepine CJ, Pettinger M, Polak JF, Ramachandran VS, Ranchalis J, Redline S, Ridker PM, Rose LM, Scharnag H, Schork NJ, Shimbo D, Shuldiner AR, Srinivasan SR, Stolk RP, Taylor HA, Thorand B, Trip MD, van Duijn CM, Verschuren WM, Wijmenga C, Winkelmann BR, Wyatt S, Young JH, Boehm BO, Caulfield MJ, Chasman DI, Davidson KW, Doevendans PA, Fitzgerald GA, Gums JG, Hakonarson H, Hillege HL, Illig T, Jarvik GP, Johnson JA, Kastelein JJ, Koenig W, März W, Mitchell BD, Murray SS, Oldehinkel AJ, Rader DJ, Reilly MP, Reiner AP, Schadt EE, Silverstein RL, Snieder H, Stanton AV, Uitterlinden AG, van der Harst P, van der Schouw YT, Samani NJ, Johnson AD, Munroe PB, de Bakker PI, Zhu X, Levy D, Keating BJ, Asselbergs FW. Loci influencing blood pressure identified using a cardiovascular gene-centric array. Hum Mol Genet. 2013 Apr 15; 22(8):1663-78. 14. Ducrocq G, Amarenco P, Labreuche J, Alberts MJ, Mas JL, Ohman EM, Goto S, Lavallée P, Bhatt DL, Steg PG. A history of stroke/transient ischemic attack indicates high risks of cardiovascular event and hemorrhagic stroke in patients with coronary artery disease. Circulation. 2013 Feb 12; 127(6):730-8. 15. Bhatt DL, Cavender MA. Are all clinical trial sites created equal? J Am Coll Cardiol. 2013 Feb 5; 61(5):580-1. 16. Tam LM, Fonarow GC, Bhatt DL, Grau-Sepulveda MV, Hernandez AF, Peterson ED, Schwamm LH, Giugliano RP. Achievement of guideline-concordant care and in-hospital outcomes in patients with coronary artery disease in teaching and nonteaching hospitals: results from the get with the guidelines-coronary artery disease program. Circ Cardiovasc Qual Outcomes. 2013 Jan 1; 6(1):58-65. 17. Jacobs AK, Kushner FG, Ettinger SM, Guyton RA, Anderson JL, Ohman EM, Albert NM, Antman EM, Arnett DK, Bertolet M, Bhatt DL, Brindis RG, Creager MA, Demets DL, Dickersin K, Fonarow GC, Gibbons RJ, Halperin JL, Hochman JS, Koster MA, Normand SL, Ortiz E, Peterson ED, Roach WH, Sacco RL, Smith SC, Stevenson WG, Tomaselli GF, Yancy CW, Zoghbi WA, Harold JG, He Y, Mangu PB, Qaseem A, Sayre MR, Somerfield MR. ACCF/AHA Clinical Practice Guideline Methodology Summit Report: A Report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines. J Am Coll Cardiol. 2013 Jan 15; 61(2):213-65. 18. Jacobs AK, Kushner FG, Ettinger SM, Guyton RA, Anderson JL, Ohman EM, Albert NM, Antman EM, Arnett DK, Bertolet M, Bhatt DL, Brindis RG, Creager MA, Demets DL, Dickersin K, Fonarow GC, Gibbons RJ, Halperin JL, Hochman JS, Koster MA, Normand SL, Ortiz E, Peterson ED, Roach WH, Sacco RL, Smith SC, Stevenson WG, Tomaselli GF, Yancy CW, Zoghbi WA, Harold JG, He Y, Mangu PB, Qaseem A, Sayre MR, Somerfield MR, Jacobs AK, Anderson JL, Halperin JL, Albert NM, Creager MA, Demets DL, Ettinger SM, Guyton RA, Hochman JS, Kushner FG, Ohman EM, Stevenson WG, Yancy CW. ACCF/AHA Clinical Practice Guideline Methodology Summit Report: A Report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines. Circulation. 2013 Jan 15; 127(2):268-310. 19. Huang PH, Croce KJ, Bhatt DL, Resnic FS. Recommendations for management of antiplatelet therapy in patients undergoing elective noncardiac surgery after coronary stent implantation. Crit Pathw Cardiol. 2012 Dec; 11(4):177-85. 20. Feres F, Costa RA, Bhatt DL, Leon MB, Botelho RV, King SB, de Paula JE, Mangione JA, Salvadori D, Gusmão MO, Castello H, Nicolela E, Perin MA, Devito FS, Marin-Neto JA, Abizaid A. Optimized Duration of Clopidogrel Therapy Following Treatment with the Endeavor Zotarolimus-Eluting Stent in Real-World Clinical Practice (OPTIMIZE) Trial: Rationale and design of a large-scale, randomized, multicenter study. Am Heart J. 2012 Dec; 164(6):810-816.e3. 21. Rassi AN, Cavender MA, Fonarow GC, Cannon CP, Hernandez AF, Peterson ED, Peacock WF, Laskey WK, Rosas SE, Zhao X, Schwamm LH, Bhatt DL. Temporal trends and predictors in the use of aldosterone antagonists post-acute myocardial infarction. J Am Coll Cardiol. 2013 Jan 8; 61(1):35-40. 22. Depta JP, Bhatt DL. Antiplatelet therapy and proton pump inhibition: cause for concern? Curr Opin Cardiol. 2012 Nov; 27(6):642-50. 23. Bangalore S, Steg G, Deedwania P, Crowley K, Eagle KA, Goto S, Ohman EM, Cannon CP, Smith SC, Zeymer U, Hoffman EB, Messerli FH, Bhatt DL. ß-Blocker use and clinical outcomes in stable outpatients with and without coronary artery disease. JAMA. 2012 Oct 3; 308(13):1340-9. 24. Ghosh D, Kuchroo P, Viswanathan C, Sachan S, Shah B, Bhatt D, Parasramani S, Savant S. Efficacy and Safety of Autologous Cultured Melanocytes Delivered on Poly (dl-Lactic Acid) Film: A Prospective, Open-Label, Randomized, Multicenter Study. Dermatol Surg. 2012 Dec; 38(12):1981-90. 25. Capodanno D, Bhatt DL, Goto S, O'Donoghue ML, Moliterno DJ, Tamburino C, Angiolillo DJ. Safety and efficacy of protease-activated receptor-1 antagonists in patients with coronary artery disease: a meta-analysis of randomized clinical trials. J Thromb Haemost. 2012 Oct; 10(10):2006-15. 26. Fuster V, Bhatt DL, Califf RM, Michelson AD, Sabatine MS, Angiolillo DJ, Bates ER, Cohen DJ, Coller BS, Furie B, Hulot JS, Mann KG, Mega JL, Musunuru K, O'Donnell CJ, Price MJ, Schneider DJ, Simon DI, Weitz JI, Williams MS, Hoots WK, Rosenberg YD, Hasan AA. Guided antithrombotic therapy: current status and future research direction: report on a National Heart, Lung and Blood Institute working group. Circulation. 2012 Sep 25; 126(13):1645-62. 27. Bhatt DL. Antiplatelet therapy following myocardial infarction in patients with diabetes. JAMA. 2012 Sep 5; 308(9):921-2. 28. Bhatt DL. EXAMINATION of new drug-eluting stents--top of the class! Lancet. 2012 Oct 27; 380(9852):1453-5. 29. Somma KA, Bhatt DL, Fonarow GC, Cannon CP, Cox M, Laskey W, Peacock WF, Hernandez AF, Peterson ED, Schwamm L, Saxon LA. Guideline adherence after ST-segment elevation versus non-ST segment elevation myocardial infarction. Circ Cardiovasc Qual Outcomes. 2012 Sep 1; 5(5):654-61. 30. Holmes DR, Mack MJ, Kaul S, Agnihotri A, Alexander KP, Bailey SR, Calhoon JH, Carabello BA, Desai MY, Edwards FH, Francis GS, Gardner TJ, Kappetein AP, Linderbaum JA, Mukherjee C, Mukherjee D, Otto CM, Ruiz CE, Sacco RL, Smith D, Thomas JD, Harrington RA, Bhatt DL, Ferrari VA, Fisher JD, Garcia MJ, Gardner TJ, Gentile F, Gilson MF, Hernandez AF, Jacobs AK, Kaul S, Linderbaum JA, Moliterno DJ, Weitz HH. 2012 ACCF/AATS/SCAI/STS expert consensus document on transcatheter aortic valve replacement: developed in collabration with the American Heart Association, American Society of Echocardiography, European Association for Cardio-Thoracic Surgery, Heart Failure Society of America, Mended Hearts, Society of Cardiovascular Anesthesiologists, Society of Cardiovascular Computed Tomography, and Society for Cardiovascular Magnetic Resonance. J Thorac Cardiovasc Surg. 2012 Sep; 144(3):e29-84. 31. Kar S, Bhatt DL. Anticoagulants for the treatment of acute coronary syndrome in the era of new oral agents. Coron Artery Dis. 2012 Sep; 23(6):380-90. 32. Banerjee S, Xu H, Fuh E, Nguyen KT, Garcia JA, Brilakis ES, Bhatt DL. Endothelial progenitor cell response to antiproliferative drug exposure. Atherosclerosis. 2012 Nov; 225(1):91-8. 33. Roe MT, Armstrong PW, Fox KA, White HD, Prabhakaran D, Goodman SG, Cornel JH, Bhatt DL, Clemmensen P, Martinez F, Ardissino D, Nicolau JC, Boden WE, Gurbel PA, Ruzyllo W, Dalby AJ, McGuire DK, Leiva-Pons JL, Parkhomenko A, Gottlieb S, Topacio GO, Hamm C, Pavlides G, Goudev AR, Oto A, Tseng CD, Merkely B, Gasparovic V, Corbalan R, Cinteza M, McLendon RC, Winters KJ, Brown EB, Lokhnygina Y, Aylward PE, Huber K, Hochman JS, Ohman EM. Prasugrel versus clopidogrel for acute coronary syndromes without revascularization. N Engl J Med. 2012 Oct 4; 367(14):1297-309. 34. Boyer NM, Laskey WK, Cox M, Hernandez AF, Peterson ED, Bhatt DL, Cannon CP, Fonarow GC. Trends in clinical, demographic, and biochemical characteristics of patients with acute myocardial infarction from 2003 to 2008: a report from the american heart association get with the guidelines coronary artery disease program. J Am Heart Assoc. 2012 Aug; 1(4):e001206. 35. Kumbhani DJ, Fonarow GC, Cannon CP, Hernandez AF, Peterson ED, Peacock WF, Laskey WK, Pan W, Schwamm LH, Bhatt DL. Predictors of adherence to performance measures in patients with acute myocardial infarction. Am J Med. 2013 Jan; 126(1):74.e1-9. 36. Focks JJ, Brouwer MA, van Oijen MG, Lanas A, Bhatt DL, Verheugt FW. Concomitant use of clopidogrel and proton pump inhibitors: impact on platelet function and clinical outcome- a systematic review. Heart. 2013 Apr; 99(8):520-7. 37. Theodos G, Raymond C, Becker MC, Thornton J, Ellis SG, Bhatt DL, Raymond RE. Arteriotomy closure device safety after percutaneous coronary intervention in the direct thrombin inhibitor era: A comparative study. Catheter Cardiovasc Interv. 2013 Feb; 81(2):294-300. 38. Udell JA, Steg PG, Scirica BM, Smith SC, Ohman EM, Eagle KA, Goto S, Cho JI, Bhatt DL. Living alone and cardiovascular risk in outpatients at risk of or with atherothrombosis. Arch Intern Med. 2012 Jul 23; 172(14):1086-95. 39. Murthy VL, Desai NR, Vora A, Bhatt DL. Increasing proportion of clinical trials using noninferiority end points. Clin Cardiol. 2012 Sep; 35(9):522-3. 40. Udell JA, Scirica BM, Braunwald E, Raz I, Gabriel Steg P, Davidson J, Hirshberg B, Bhatt DL. Statin and aspirin therapy for the prevention of cardiovascular events in patients with type 2 diabetes mellitus. Clin Cardiol. 2012; 35(12):722-9. 41. Wilson PW, D'Agostino R, Bhatt DL, Eagle K, Pencina MJ, Smith SC, Alberts MJ, Dallongeville J, Goto S, Hirsch AT, Liau CS, Ohman EM, Röther J, Reid C, Mas JL, Steg PG. An international model to predict recurrent cardiovascular disease. Am J Med. 2012 Jul; 125(7):695-703.e1. 42. Bhatt DL, Bakris GL. The promise of renal denervation. Cleve Clin J Med. 2012 Jul; 79(7):498-500. 43. Angiolillo DJ, Schneider DJ, Bhatt DL, French WJ, Price MJ, Saucedo JF, Shaburishvili T, Huber K, Prats J, Liu T, Harrington RA, Becker RC. Pharmacodynamic effects of cangrelor and clopidogrel: the platelet function substudy from the cangrelor versus standard therapy to achieve optimal management of platelet inhibition (CHAMPION) trials. J Thromb Thrombolysis. 2012 Jul; 34(1):44-55. 44. O'Donoghue ML, Bhatt DL, Flather MD, Goto S, Angiolillo DJ, Goodman SG, Zeymer U, Aylward PE, Montalescot G, Ziecina R, Kobayashi H, Ren F, Wiviott SD. Atopaxar and its effects on markers of platelet activation and inflammation: results from the LANCELOT CAD program. J Thromb Thrombolysis. 2012 Jul; 34(1):36-43. 45. Medina HM, Cannon CP, Fonarow GC, Grau-Sepulveda MV, Hernandez AF, Frank Peacock W, Laskey W, Peterson ED, Schwamm L, Bhatt DL. Reperfusion strategies and quality of care in 5339 patients age 80 years or older presenting with ST-elevation myocardial infarction: analysis from get with the guidelines-coronary artery disease. Clin Cardiol. 2012 Oct; 35(10):632-40. 46. Vasaiwala S, Cannon CP, Fonarow GC, Peacock WF, Laskey W, Schwamm LH, Liang L, Hernandez AF, Peterson ED, Rosas SE, Bhatt DL. Quality of care and outcomes among patients with acute myocardial infarction by level of kidney function at admission: report from the get with the guidelines coronary artery disease program. Clin Cardiol. 2012 Sep; 35(9):541-7. 47. Bangalore S, Fonarow GC, Peterson ED, Hellkamp AS, Hernandez AF, Laskey W, Peacock WF, Cannon CP, Schwamm LH, Bhatt DL. Age and gender differences in quality of care and outcomes for patients with ST-segment elevation myocardial infarction. Am J Med. 2012 Oct; 125(10):1000-9. 48. Bansilal S, Bhatt DL. Clopidogrel resistance - A clear problem with an unclear solution. Indian Heart J. 2012 Jul-Aug; 64(4):353-5. 49. Subherwal S, Bhatt DL, Li S, Wang TY, Thomas L, Alexander KP, Patel MR, Ohman EM, Gibler WB, Peterson ED, Roe MT. Polyvascular disease and long-term cardiovascular outcomes in older patients with non-ST-segment-elevation myocardial infarction. Circ Cardiovasc Qual Outcomes. 2012 Jul 1; 5(4):541-9. 50. Depta JP, Fowler J, Novak E, Katzan I, Bakdash S, Kottke-Marchant K, Bhatt DL. Clinical outcomes using a platelet function-guided approach for secondary prevention in patients with ischemic stroke or transient ischemic attack. Stroke. 2012 Sep; 43(9):2376-81. 51. Duval S, Massaro JM, Jaff MR, Boden WE, Alberts MJ, Califf RM, Eagle KA, D'Agostino RB, Pedley A, Fonarow GC, Murabito JM, Steg PG, Bhatt DL, Hirsch AT. An evidence-based score to detect prevalent peripheral artery disease (PAD). Vasc Med. 2012 Oct; 17(5):342-51. 52. Cantú-Brito C, Chiquete E, Ruiz-Sandoval JL, Gaxiola E, Albuquerque DC, Corbalán R, Ramos A, Bhatt DL, Steg PG. Atherothrombotic disease, traditional risk factors, and 4-year mortality in a Latin American population: the REACH Registry. Clin Cardiol. 2012 Aug; 35(8):451-7. 53. Welsh RC, Rao SV, Zeymer U, Thompson VP, Huber K, Kochman J, McClure MW, Gretler DD, Bhatt DL, Gibson CM, Angiolillo DJ, Gurbel PA, Berdan LG, Paynter G, Leonardi S, Madan M, French WJ, Harrington RA. A randomized, double-blind, active-controlled phase 2 trial to evaluate a novel selective and reversible intravenous and oral P2Y12 inhibitor elinogrel versus clopidogrel in patients undergoing nonurgent percutaneous coronary intervention: the INNOVATE-PCI trial. Circ Cardiovasc Interv. 2012 Jun; 5(3):336-46. 54. Steinberg BA, Zhao X, Heidenreich PA, Peterson ED, Bhatt DL, Cannon CP, Hernandez AF, Fonarow GC. Trends in patients hospitalized with heart failure and preserved left ventricular ejection fraction: prevalence, therapies, and outcomes. Circulation. 2012 Jul 3; 126(1):65-75. 55. Bangalore S, Kumar S, Fusaro M, Amoroso N, Attubato MJ, Feit F, Bhatt DL, Slater J. Short- and long-term outcomes with drug-eluting and bare-metal coronary stents: a mixed-treatment comparison analysis of 117 762 patient-years of follow-up from randomized trials. Circulation. 2012 Jun 12; 125(23):2873-91. 56. Timur AA, Murugesan G, Zhang L, Aung PP, Barnard J, Wang QK, Gaussem P, Silverstein RL, Bhatt DL, Kottke-Marchant K. P2RY1 and P2RY12 polymorphisms and on-aspirin platelet reactivity in patients with coronary artery disease. Int J Lab Hematol. 2012 Oct; 34(5):473-83. 57. Kandzari DE, Bhatt DL, Sobotka PA, O'Neill WW, Esler M, Flack JM, Katzen BT, Leon MB, Massaro JM, Negoita M, Oparil S, Rocha-Singh K, Straley C, Townsend RR, Bakris G. Catheter-based renal denervation for resistant hypertension: rationale and design of the SYMPLICITY HTN-3 Trial. Clin Cardiol. 2012 Sep; 35(9):528-35. 58. Bashore TM, Balter S, Barac A, Byrne JG, Cavendish JJ, Chambers CE, Hermiller JB, Kinlay S, Landzberg JS, Laskey WK, McKay CR, Miller JM, Moliterno DJ, Moore JW, Oliver-McNeil SM, Popma JJ, Tommaso AC, Harrington RA, Bates ER, Bhatt DL, Bridges CR, Eisenberg MJ, Ferrari VA, Fisher JD, Gardner T, Gentile F, Gilson MF, Hlatky MA, Jacobs AK, Kaul S, Moliterno DJ, Mukherjee D, Rosenson RS, Weitz HH, Wesley DJ. 2012 American College of Cardiology Foundation/Society for Cardiovascular Angiography and Interventions expert consensus document on cardiac catheterization laboratory standards update: American College of Cardiology Foundation Task Force on expert consensus documents Society of Thoracic Surgeons Society for Vascular Medicine. Catheter Cardiovasc Interv. 2012 Sep 1; 80(3):E37-49. 59. Leonardi S, Mahaffey KW, White HD, Gibson CM, Stone GW, Steg GW, Hamm CW, Price MJ, Todd M, Dietrich M, Gallup D, Liu T, Skerjanec S, Harrington RA, Bhatt DL. Rationale and design of the Cangrelor versus standard therapy to acHieve optimal Management of Platelet InhibitiON PHOENIX trial. Am Heart J. 2012 May; 163(5):768-776.e2. 60. Bansilal S, Bhatt DL. Declining coronary artery bypass-related mortality: more than meets the eye? Clin Cardiol. 2012 May; 35(5):261-2. 61. Holmes DR, Mack MJ, Kaul S, Agnihotri A, Alexander KP, Bailey SR, Calhoon JH, Carabello BA, Desai MY, Edwards FH, Francis GS, Gardner TJ, Kappetein AP, Linderbaum JA, Mukherjee C, Mukherjee D, Otto CM, Ruiz CE, Sacco RL, Smith D, Thomas JD, Harrington RA, Bhatt DL, Ferrari VA, Fisher JD, Garcia MJ, Gardner TJ, Gentile F, Gilson MF, Hernandez AF, Jacobs AK, Kaul S, Linderbaum JA, Moliterno DJ, Weitz HH. 2012 ACCF/AATS/SCAI/STS expert consensus document on transcatheter aortic valve replacement: developed in collaboration with the American Heart Association, American Society of Echocardiography, European Association for Cardio-Thoracic Surgery, Heart Failure Society of America, Mended Hearts, Society of Cardiovascular Anesthesiologists, Society of Cardiovascular Computed Tomography, and Society for Cardiovascular Magnetic Resonance. Catheter Cardiovasc Interv. 2012 Jun 1; 79(7):1023-82. 62. Venkitachalam L, Wang K, Porath A, Corbalan R, Hirsch AT, Cohen DJ, Smith SC, Ohman EM, Steg PG, Bhatt DL, Magnuson EA. Global variation in the prevalence of elevated cholesterol in outpatients with established vascular disease or 3 cardiovascular risk factors according to national indices of economic development and health system performance. Circulation. 2012 Apr 17; 125(15):1858-69. 63. Frelinger AL, Lee RD, Mulford DJ, Wu J, Nudurupati S, Nigam A, Brooks JK, Bhatt DL, Michelson AD. A randomized, 2-period, crossover design study to assess the effects of dexlansoprazole, lansoprazole, esomeprazole, and omeprazole on the steady-state pharmacokinetics and pharmacodynamics of clopidogrel in healthy volunteers. J Am Coll Cardiol. 2012 Apr 3; 59(14):1304-11. 64. Bhatt DL, Paré G, Eikelboom JW, Simonsen KL, Emison ES, Fox KA, Steg PG, Montalescot G, Bhakta N, Hacke W, Flather MD, Mak KH, Cacoub P, Creager MA, Berger PB, Steinhubl SR, Murugesan G, Mehta SR, Kottke-Marchant K, Lincoff AM, Topol EJ. The relationship between CYP2C19 polymorphisms and ischaemic and bleeding outcomes in stable outpatients: the CHARISMA genetics study. Eur Heart J. 2012 Sep; 33(17):2143-50. 65. Schauer PR, Kashyap SR, Wolski K, Brethauer SA, Kirwan JP, Pothier CE, Thomas S, Abood B, Nissen SE, Bhatt DL. Bariatric surgery versus intensive medical therapy in obese patients with diabetes. N Engl J Med. 2012 Apr 26; 366(17):1567-76. 66. Maron BA, Bhatt DL, Nykiel M, Kinlay S, Waxman AB. Protocol for vasoreactivity testing with epoprostenol in pulmonary hypertension. Crit Pathw Cardiol. 2012 Mar; 11(1):40-2. 67. Hsich EM, Grau-Sepulveda MV, Hernandez AF, Peterson ED, Schwamm LH, Bhatt DL, Fonarow GC. Sex differences in in-hospital mortality in acute decompensated heart failure with reduced and preserved ejection fraction. Am Heart J. 2012 Mar; 163(3):430-7, 437.e1-3. 68. Vivo RP, Krim SR, Krim NR, Zhao X, Hernandez AF, Peterson ED, Piña IL, Bhatt DL, Schwamm LH, Fonarow GC. Care and outcomes of Hispanic patients admitted with heart failure with preserved or reduced ejection fraction: findings from get with the guidelines-heart failure. Circ Heart Fail. 2012 Mar 1; 5(2):167-75. 69. Mountantonakis SE, Grau-Sepulveda MV, Bhatt DL, Hernandez AF, Peterson ED, Fonarow GC. Presence of atrial fibrillation is independently associated with adverse outcomes in patients hospitalized with heart failure: an analysis of get with the guidelines-heart failure. Circ Heart Fail. 2012 Mar 1; 5(2):191-201. 70. Reid CM, Ademi Z, Nelson MR, Connor G, Chew DP, Shiel L, Smeath A, De Looze F, Steg PG, Bhatt DL, Liew D. Outcomes from the REACH Registry for Australian general practice patients with or at high risk of atherothrombosis. Med J Aust. 2012 Feb 20; 196(3):193-7. 71. Brilakis ES, Banerjee S, Shunk KA, Bhatt DL. Drug-eluting versus bare-metal stents in saphenous vein graft lesions. Lancet. 2012 Feb 18; 379(9816):615; author reply 615-6. 72. Subherwal S, Peterson ED, Chen AY, Roe MT, Washam JB, Gage BF, Bach RG, Bhatt DL, Wiviott SD, Lopes RD, Alexander KP, Wang TY. Admission international normalized ratio levels, early treatment strategies, and major bleeding risk among non-ST-segment-elevation myocardial infarction patients on home warfarin therapy: insights from the National Cardiovascular Data Registry. Circulation. 2012 Mar 20; 125(11):1414-23. 73. White HD, Chew DP, Dauerman HL, Mahaffey KW, Gibson CM, Stone GW, Gruberg L, Harrington RA, Bhatt DL. Reduced immediate ischemic events with cangrelor in PCI: a pooled analysis of the CHAMPION trials using the universal definition of myocardial infarction. Am Heart J. 2012 Feb; 163(2):182-90.e4. 74. Abola MT, Bhatt DL, Duval S, Cacoub PP, Baumgartner I, Keo H, Creager MA, Brennan DM, Steg PG, Hirsch AT. Fate of individuals with ischemic amputations in the REACH Registry: three-year cardiovascular and limb-related outcomes. Atherosclerosis. 2012 Apr; 221(2):527-35. 75. Moukarbel GV, Bhatt DL. Antiplatelet therapy and proton pump inhibition: clinician update. Circulation. 2012 Jan 17; 125(2):375-80. 76. Qian F, Ling FS, Deedwania P, Hernandez AF, Fonarow GC, Cannon CP, Peterson ED, Peacock WF, Kaltenbach LA, Laskey WK, Schwamm LH, Bhatt DL. Care and outcomes of Asian-American acute myocardial infarction patients: findings from the American Heart Association Get With The Guidelines-Coronary Artery Disease program. Circ Cardiovasc Qual Outcomes. 2012 Jan; 5(1):126-33. 77. Huang PH, Kim CX, Lerman A, Cannon CP, Dai D, Laskey W, Peacock WF, Hernandez AF, Peterson ED, Smith EE, Fonarow GC, Schwamm LH, Bhatt DL. Trends in smoking cessation counseling: experience from American Heart Association-get with the guidelines. Clin Cardiol. 2012; 35(7):396-403. 78. Yeo KK, Li S, Amsterdam EA, Wang TY, Bhatt DL, Saucedo JF, Kontos MC, Roe MT, French WJ. Comparison of clinical characteristics, treatments and outcomes of patients with ST-elevation acute myocardial infarction with versus without new or presumed new left bundle branch block (from NCDR®). Am J Cardiol. 2012 Feb 15; 109(4):497-501. 79. Mega JL, Braunwald E, Wiviott SD, Bassand JP, Bhatt DL, Bode C, Burton P, Cohen M, Cook-Bruns N, Fox KA, Goto S, Murphy SA, Plotnikov AN, Schneider D, Sun X, Verheugt FW, Gibson CM. Rivaroxaban in patients with a recent acute coronary syndrome. N Engl J Med. 2012 Jan 5; 366(1):9-19. 80. Krim SR, Vivo RP, Krim NR, Cox M, Hernandez AF, Peterson ED, Fonarow GC, Piña IL, Schwamm LH, Bhatt DL. Regional differences in clinical profile, quality of care, and outcomes among Hispanic patients hospitalized with acute myocardial infarction in the Get with Guidelines-Coronary Artery Disease (GWTG-CAD) registry. Am Heart J. 2011 Dec; 162(6):988-995.e4. 81. Scirica BM, Bhatt DL, Braunwald E, Steg PG, Davidson J, Hirshberg B, Ohman P, Price DL, Chen R, Udell J, Raz I. The design and rationale of the saxagliptin assessment of vascular outcomes recorded in patients with diabetes mellitus-thrombolysis in myocardial infarction (SAVOR-TIMI) 53 study. Am Heart J. 2011 Nov; 162(5):818-825.e6. 82. Bangalore S, Bhatt DL. Images in cardiovascular medicine. Right heart catheterization, coronary angiography, and percutaneous coronary intervention. Circulation. 2011 Oct 25; 124(17):e428-33. 83. Motivala AA, Cannon CP, Srinivas VS, Dai D, Hernandez AF, Peterson ED, Bhatt DL, Fonarow GC. Changes in myocardial infarction guideline adherence as a function of patient risk: an end to paradoxical care? J Am Coll Cardiol. 2011 Oct 18; 58(17):1760-5. 84. Eapen ZJ, Fonarow GC, Dai D, O'Brien SM, Schwamm LH, Cannon CP, Heidenreich PA, Bhatt DL, Peterson ED, Hernandez AF. Comparison of composite measure methodologies for rewarding quality of care: an analysis from the American Heart Association's Get With The Guidelines program. Circ Cardiovasc Qual Outcomes. 2011 Nov 1; 4(6):610-8. 85. Hackam DG, Woodward M, Newby LK, Bhatt DL, Shao M, Smith EE, Donner A, Mamdani M, Douketis JD, Arima H, Chalmers J, MacMahon S, Tirschwell DL, Psaty BM, Bushnell CD, Aguilar MI, Capampangan DJ, Werring DJ, De Rango P, Viswanathan A, Danchin N, Cheng CL, Yang YH, Verdel BM, Lai MS, Kennedy J, Uchiyama S, Yamaguchi T, Ikeda Y, Mrkobrada M. Statins and intracerebral hemorrhage: collaborative systematic review and meta-analysis. Circulation. 2011 Nov 15; 124(20):2233-42. 86. Smolderen KG, Wang K, de Pouvourville G, Brüggenjürgen B, Röther J, Zeymer U, Parhofer KG, Steg PG, Bhatt DL, Magnuson EA. Two-year vascular hospitalisation rates and associated costs in patients at risk of atherothrombosis in France and Germany: highest burden for peripheral arterial disease. Eur J Vasc Endovasc Surg. 2012 Feb; 43(2):198-207. 87. Ademi Z, Reid CM, Hollingsworth B, Stoelwinder J, Steg PG, Bhatt DL, Vale M, Liew D. Cost-effectiveness of optimizing use of statins in Australia: using outpatient data from the REACH Registry. Clin Ther. 2011 Oct; 33(10):1456-65. 88. Meadows TA, Bhatt DL, Cannon CP, Gersh BJ, Röther J, Goto S, Liau CS, Wilson PW, Salette G, Smith SC, Steg PG. Ethnic differences in cardiovascular risks and mortality in atherothrombotic disease: insights from the Reduction of Atherothrombosis for Continued Health (REACH) registry. Mayo Clin Proc. 2011 Oct; 86(10):960-7. 89. Faxon DP, Eikelboom JW, Berger PB, Holmes DR, Bhatt DL, Moliterno DJ, Becker RC, Angiolillo DJ. Antithrombotic therapy in patients with atrial fibrillation undergoing coronary stenting: a North American perspective: executive summary. Circ Cardiovasc Interv. 2011 Oct 1; 4(5):522-34. 90. Chen HY, Sinha AK, Choy JS, Zheng H, Sturek M, Bigelow B, Bhatt DL, Kassab GS. Mis-sizing of stent promotes intimal hyperplasia: impact of endothelial shear and intramural stress. Am J Physiol Heart Circ Physiol. 2011 Dec; 301(6):H2254-63. 91. Lewis WR, Fonarow GC, Grau-Sepulveda MV, Smith EE, Bhatt DL, Hernandez AF, Olson D, Peterson ED, Schwamm LH. Improvement in use of anticoagulation therapy in patients with ischemic stroke: results from Get With The Guidelines-Stroke. Am Heart J. 2011 Oct; 162(4):692-699.e2. 92. Keo HH, Baumgartner I, Hirsch AT, Duval S, Steg PG, Pasquet B, Bhatt DL, Roether J. Carotid plaque and intima-media thickness and the incidence of ischemic events in patients with atherosclerotic vascular disease. Vasc Med. 2011 Oct; 16(5):323-30. 93. Venketasubramanian N, Röther J, Bhatt DL, Pasquet B, Mas JL, Alberts MJ, Hill MD, Aichner F, Steg PG. Two-year vascular event rates in patients with symptomatic cerebrovascular disease: the REACH registry. Cerebrovasc Dis. 2011; 32(3):254-60. 94. Klein L, Grau-Sepulveda MV, Bonow RO, Hernandez AF, Williams MV, Bhatt DL, Fonarow GC. Quality of care and outcomes in women hospitalized for heart failure. Circ Heart Fail. 2011 Sep; 4(5):589-98. 95. Wang TY, Dai D, Hernandez AF, Bhatt DL, Heidenreich PA, Fonarow GC, Peterson ED. The importance of consistent, high-quality acute myocardial infarction and heart failure care results from the American Heart Association's Get with the Guidelines Program. J Am Coll Cardiol. 2011 Aug 2; 58(6):637-44. 96. Bangalore S, Bhatt DL. Femoral arterial access and closure. Circulation. 2011 Aug 2; 124(5):e147-56. 97. Medina HM, Cannon CP, Zhao X, Hernandez AF, Bhatt DL, Peterson ED, Liang L, Fonarow GC. Quality of acute myocardial infarction care and outcomes in 33,997 patients aged 80 years or older: findings from Get With The Guidelines-Coronary Artery Disease (GWTG-CAD). Am Heart J. 2011 Aug; 162(2):283-290.e2. 98. Faxon DP, Eikelboom JW, Berger PB, Holmes DR, Bhatt DL, Moliterno DJ, Becker RC, Angiolillo DJ. Consensus document: antithrombotic therapy in patients with atrial fibrillation undergoing coronary stenting. A North-American perspective. Thromb Haemost. 2011 Oct; 106(4):572-84. 99. Alexander JH, Lopes RD, James S, Kilaru R, He Y, Mohan P, Bhatt DL, Goodman S, Verheugt FW, Flather M, Huber K, Liaw D, Husted SE, Lopez-Sendon J, De Caterina R, Jansky P, Darius H, Vinereanu D, Cornel JH, Cools F, Atar D, Leiva-Pons JL, Keltai M, Ogawa H, Pais P, Parkhomenko A, Ruzyllo W, Diaz R, White H, Ruda M, Geraldes M, Lawrence J, Harrington RA, Wallentin L. Apixaban with antiplatelet therapy after acute coronary syndrome. N Engl J Med. 2011 Aug 25; 365(8):699-708. 100. Yousuf O, Bhatt DL. The evolution of antiplatelet therapy in cardiovascular disease. Nat Rev Cardiol. 2011 Oct; 8(10):547-59. 101. Aronow WS, Fleg JL, Pepine CJ, Artinian NT, Bakris G, Brown AS, Ferdinand KC, Ann Forciea M, Frishman WH, Jaigobin C, Kostis JB, Mancia G, Oparil S, Ortiz E, Reisin E, Rich MW, Schocken DD, Weber MA, Wesley DJ, Harrington RA, Bates ER, Bhatt DL, Bridges CR, Eisenberg MJ, Ferrari VA, Fisher JD, Gardner TJ, Gentile F, Gilson MF, Hlatky MA, Jacobs AK, Kaul S, Moliterno DJ, Mukherjee D, Rosenson RS, Stein JH, Weitz HH, Wesley DJ. ACCF/AHA 2011 expert consensus document on hypertension in the elderly: a report of the American College of Cardiology Foundation Task Force on Clinical Expert Consensus Documents developed in collaboration with the American Academy of Neurology, American Geriatrics Society, American Society for Preventive Cardiology, American Society of Hypertension, American Society of Nephrology, Association of Black Cardiologists, and European Society of Hypertension. J Am Soc Hypertens. 2011 Jul-Aug; 5(4):259-352. 102. Ademi Z, Liew D, Hollingsworth B, Steg PG, Bhatt DL, Reid CM. Is It Cost-Effective To Increase Aspirin Use in Outpatient Settings for Primary or Secondary Prevention? Simulation Data from the REACH Registry Australian Cohort. Cardiovasc Ther. 2013 Feb; 31(1):45-52. 103. Berger JS, Bhatt DL, Steg PG, Steinhubl SR, Montalescot G, Shao M, Hacke W, Fox KA, Berger PB, Topol EJ, Lincoff AM. Bleeding, mortality, and antiplatelet therapy: results from the Clopidogrel for High Atherothrombotic Risk and Ischemic Stabilization, Management, and Avoidance (CHARISMA) trial. Am Heart J. 2011 Jul; 162(1):98-105.e1. 104. Barthélémy O, Limbourg T, Collet JP, Beygui F, Silvain J, Bellemain-Appaix A, Cayla G, Chastre T, Baumgartner I, Röther J, Zeymer U, Bhatt DL, Steg G, Montalescot G. Impact of non-steroidal anti-inflammatory drugs (NSAIDs) on cardiovascular outcomes in patients with stable atherothrombosis or multiple risk factors. Int J Cardiol. 2013 Mar 10; 163(3):266-71. 105. Simon T, Bhatt DL, Bergougnan L, Farenc C, Pearson K, Perrin L, Vicaut E, Lacreta F, Hurbin F, Dubar M. Genetic polymorphisms and the impact of a higher clopidogrel dose regimen on active metabolite exposure and antiplatelet response in healthy subjects. Clin Pharmacol Ther. 2011 Aug; 90(2):287-95. 106. Alberts MJ, Bhatt DL, Smith SC, Röther J, Goto S, Hirsch AT, Steg PG. Risk factors and outcomes for patients with vascular disease and serious bleeding events. Heart. 2011 Sep; 97(18):1507-12. 107. Mehran R, Rao SV, Bhatt DL, Gibson CM, Caixeta A, Eikelboom J, Kaul S, Wiviott SD, Menon V, Nikolsky E, Serebruany V, Valgimigli M, Vranckx P, Taggart D, Sabik JF, Cutlip DE, Krucoff MW, Ohman EM, Steg PG, White H. Standardized bleeding definitions for cardiovascular clinical trials: a consensus report from the Bleeding Academic Research Consortium. Circulation. 2011 Jun 14; 123(23):2736-47. 108. Whellan DJ, Zhao X, Hernandez AF, Liang L, Peterson ED, Bhatt DL, Heidenreich PA, Schwamm LH, Fonarow GC. Predictors of hospital length of stay in heart failure: findings from Get With the Guidelines. J Card Fail. 2011 Aug; 17(8):649-56. 109. Bhatt DL. Evaluation of agents to reduce infarct size: it can be quite REVEALing. JAMA. 2011 May 11; 305(18):1908-9. 110. O'Donoghue ML, Bhatt DL, Wiviott SD, Goodman SG, Fitzgerald DJ, Angiolillo DJ, Goto S, Montalescot G, Zeymer U, Aylward PE, Guetta V, Dudek D, Ziecina R, Contant CF, Flather MD. Safety and tolerability of atopaxar in the treatment of patients with acute coronary syndromes: the lessons from antagonizing the cellular effects of Thrombin–Acute Coronary Syndromes Trial. Circulation. 2011 May 3; 123(17):1843-53. 111. Wiviott SD, Flather MD, O'Donoghue ML, Goto S, Fitzgerald DJ, Cura F, Aylward P, Guetta V, Dudek D, Contant CF, Angiolillo DJ, Bhatt DL. Randomized trial of atopaxar in the treatment of patients with coronary artery disease: the lessons from antagonizing the cellular effect of Thrombin–Coronary Artery Disease Trial. Circulation. 2011 May 3; 123(17):1854-63. 112. Sakhuja R, Yeh RW, Bhatt DL. Anticoagulant agents in acute coronary syndromes. Curr Probl Cardiol. 2011 Apr; 36(4):127-68. 113. Morrell J, Zeymer U, Baumgartner I, Limbourg T, Röther J, Bhatt DL, Steg PG. Differences in management and outcomes between male and female patients with atherothrombotic disease: results from the REACH Registry in Europe. Eur J Cardiovasc Prev Rehabil. 2011 Apr; 18(2):270-7. 114. Allen LA, Hernandez AF, Peterson ED, Curtis LH, Dai D, Masoudi FA, Bhatt DL, Heidenreich PA, Fonarow GC. Discharge to a skilled nursing facility and subsequent clinical outcomes among older patients hospitalized for heart failure. Circ Heart Fail. 2011 May; 4(3):293-300. 115. Hermiller J, Choy JS, Svendsen M, Bigelow B, Fouts AM, Hall J, Parr K, Ball M, Sinha A, Bhatt DL, Kassab GS. A nonimaging catheter for measurement of coronary artery lumen area: a first in man pilot study. Catheter Cardiovasc Interv. 2011 Aug 1; 78(2):202-10. 116. Weber M, Bhatt DL, Brennan DM, Hankey GJ, Steinhubl SR, Johnston SC, Montalescot G, Mak KH, Fox KA, Easton DJ, Topol EJ, Hamm CW. High-sensitivity C-reactive protein and clopidogrel treatment in patients at high risk of cardiovascular events: a substudy from the CHARISMA trial. Heart. 2011 Apr; 97(8):626-31. 117. Bhatt DL. Glycoprotein IIb/IIIa inhibitors: do they still have a role? J Am Coll Cardiol. 2011 Mar 8; 57(10):1200-1. 118. Chen J, Shi C, Mahoney EM, Dunn ES, Rinfret S, Caro JJ, O'Brien J, El-Hadi W, Bhatt DL, Topol EJ, Cohen DJ. Economic evaluation of clopidogrel plus aspirin for secondary prevention of cardiovascular events in Canada for patients with established cardiovascular disease: Results from the CHARISMA trial. Can J Cardiol. 2011 Mar-Apr; 27(2):222-31. 119. Kumbhani DJ, Bavry AA, Harvey JE, de Souza R, Scarpioni R, Bhatt DL, Kapadia SR. Clinical outcomes after percutaneous revascularization versus medical management in patients with significant renal artery stenosis: a meta-analysis of randomized controlled trials. Am Heart J. 2011 Mar; 161(3):622-630.e1. 120. Cacoub PP, Zeymer U, Limbourg T, Baumgartner I, Poldermans D, Röther J, Bhatt DL, Steg PG. Effects of adherence to guidelines for the control of major cardiovascular risk factors on outcomes in the REduction of Atherothrombosis for Continued Health (REACH) Registry Europe. Heart. 2011 Apr; 97(8):660-7. 121. Dallongeville J, Bhatt DL, Steg PH, Ravaud P, Wilson PW, Eagle KA, Goto S, Mas JL, Montalescot G. Relation between body mass index, waist circumference, and cardiovascular outcomes in 19,579 diabetic patients with established vascular disease: the REACH Registry. Eur J Prev Cardiol. 2012 Apr; 19(2):241-9. 122. Gharacholou SM, Hellkamp AS, Hernandez AF, Peterson ED, Bhatt DL, Yancy CW, Fonarow GC. Use and predictors of heart failure disease management referral in patients hospitalized with heart failure: insights from the Get With the Guidelines Program. J Card Fail. 2011 May; 17(5):431-9. 123. Fonarow GC, Smith EE, Saver JL, Reeves MJ, Bhatt DL, Grau-Sepulveda MV, Olson DM, Hernandez AF, Peterson ED, Schwamm LH. Timeliness of tissue-type plasminogen activator therapy in acute ischemic stroke: patient characteristics, hospital factors, and outcomes associated with door-to-needle times within 60 minutes. Circulation. 2011 Feb 22; 123(7):750-8. 124. Hankey GJ, Johnston SC, Easton JD, Hacke W, Mas JL, Brennan D, Mak KH, Bhatt DL, Fox KA, Topol EJ. Effect of clopidogrel plus ASA vs. ASA early after TIA and ischaemic stroke: a substudy of the CHARISMA trial. Int J Stroke. 2011 Feb; 6(1):3-9. 125. Javed U, Deedwania PC, Bhatt DL, Cannon CP, Dai D, Hernandez A, Peterson ED, Fonarow GC. Use of intensive lipid-lowering therapy in patients hospitalized with acute coronary syndrome: An analysis of 65,396 hospitalizations from 344 hospita participating in Get With The Guidelines (GWTG). Am Heart J. 2011 Feb; 161(2):418-424.e1-3. 126. Kolandaivelu K, Bhatt DL. Antiplatelet therapy in coronary heart disease prevention. Cardiol Clin. 2011 Feb; 29(1):71-85. 127. Sheikh MA, Bhatt DL, Li J, Lin S, Bartholomew JR. Usefulness of postexercise ankle-brachial index to predict all-cause mortality. Am J Cardiol. 2011 Mar 1; 107(5):778-82. 128. Banerjee S, Weideman RA, Weideman MW, Little BB, Kelly KC, Gunter JT, Tortorice KL, Shank M, Cryer B, Reilly RF, Rao SV, Kastrati A, de Lemos JA, Brilakis ES, Bhatt DL. Effect of concomitant use of clopidogrel and proton pump inhibitors after percutaneous coronary intervention. Am J Cardiol. 2011 Mar 15; 107(6):871-8. 129. Abraham NS, Hlatky MA, Antman EM, Bhatt DL, Bjorkman DJ, Clark CB, Furberg CD, Johnson DA, Kahi CJ, Laine L, Mahaffey KW, Quigley EM, Scheiman J, Sperling LS, Tomaselli GF. ACCF/ACG/AHA 2010 expert consensus document on the concomitant use of proton pump inhibitors and thienopyridines: a focused update of the ACCF/ACG/AHA 2008 expert consensus document on reducing the gastrointestinal risks of antiplatelet therapy and NSAID use. A Report of the American College of Cardiology Foundation Task Force on Expert Consensus Documents. J Am Coll Cardiol. 2010 Dec 7; 56(24):2051-66. 130. Abraham NS, Hlatky MA, Antman EM, Bhatt DL, Bjorkman DJ, Clark CB, Furberg CD, Johnson DA, Kahi CJ, Laine L, Mahaffey KW, Quigley EM, Scheiman J, Sperling LS, Tomaselli GF. ACCF/ACG/AHA 2010 expert consensus document on the concomitant use of proton pump inhibitors and thienopyridines: a focused update of the ACCF/ACG/AHA 2008 expert consensus document on reducing the gastrointestinal risks of antiplatelet therapy and NSAID use. Am J Gastroenterol. 2010 Dec; 105(12):2533-49. 131. Chiu JF, Bell AD, Herman RJ, Hill MD, Stewart JA, Cohen EA, Liau CS, Steg PG, Bhatt DL. Cardiovascular risk profiles and outcomes of Chinese living inside and outside China. Eur J Cardiovasc Prev Rehabil. 2010 Dec; 17(6):668-75. 132. Javed U, Deedwania PC, Bhatt DL, Cannon CP, Dai D, Hernandez AF, Peterson ED, Fonarow GC. Use of intensive lipid-lowering therapy in patients hospitalized with acute coronary syndrome: an analysis of 65,396 hospitalizations from 344 hospitals participating in Get With The Guidelines (GWTG). Am Heart J. 2010 Dec; 160(6):1130-6, 1136.e1-3. 133. Roussel R, Travert F, Pasquet B, Wilson PW, Smith SC, Goto S, Ravaud P, Marre M, Porath A, Bhatt DL, Steg PG. Metformin use and mortality among patients with diabetes and atherothrombosis. Arch Intern Med. 2010 Nov 22; 170(21):1892-9. 134. Cryer B, Bhatt DL, Lanza FL, Dong JF, Lichtenberger LM, Marathi UK. Low-dose aspirin-induced ulceration is attenuated by aspirin-phosphatidylcholine: a randomized clinical trial. Am J Gastroenterol. 2011 Feb; 106(2):272-7. 135. Abraham NS, Hlatky MA, Antman EM, Bhatt DL, Bjorkman DJ, Clark CB, Furberg CD, Johnson DA, Kahi CJ, Laine L, Mahaffey KW, Quigley EM, Scheiman J, Sperling LS, Tomaselli GF. ACCF/ACG/AHA 2010 Expert Consensus Document on the concomitant use of proton pump inhibitors and thienopyridines: a focused update of the ACCF/ACG/AHA 2008 expert consensus document on reducing the gastrointestinal risks of antiplatelet therapy and NSAID use: a report of the American College of Cardiology Foundation Task Force on Expert Consensus Documents. Circulation. 2010 Dec 14; 122(24):2619-33. 136. Mahoney EM, Wang K, Keo HH, Duval S, Smolderen KG, Cohen DJ, Steg G, Bhatt DL, Hirsch AT. Vascular hospitalization rates and costs in patients with peripheral artery disease in the United States. Circ Cardiovasc Qual Outcomes. 2010 Nov; 3(6):642-51. 137. Bangalore S, Kumar S, Wetterslev J, Bavry AA, Gluud C, Cutlip DE, Bhatt DL. Carotid artery stenting vs carotid endarterectomy: meta-analysis and diversity-adjusted trial sequential analysis of randomized trials. Arch Neurol. 2011 Feb; 68(2):172-84. 138. Bhatt DL, Cryer BL, Contant CF, Cohen M, Lanas A, Schnitzer TJ, Shook TL, Lapuerta P, Goldsmith MA, Laine L, Scirica BM, Murphy SA, Cannon CP. Clopidogrel with or without omeprazole in coronary artery disease. N Engl J Med. 2010 Nov 11; 363(20):1909-17. 139. Aragam KG, Bhatt DL. Antiplatelet therapy in acute coronary syndromes. J Cardiovasc Pharmacol Ther. 2011 Mar; 16(1):24-42. 140. Smolderen KG, Bell A, Lei Y, Cohen EA, Steg PG, Bhatt DL, Mahoney EM. One-year costs associated with cardiovascular disease in Canada: Insights from the REduction of Atherothrombosis for Continued Health (REACH) registry. Can J Cardiol. 2010 Oct; 26(8):297-305. 141. Kumbhani DJ, Bhatt DL. Secondary prevention of stroke: can we do better than aspirin? Lancet Neurol. 2010 Oct; 9(10):942-3. 142. Bonello L, Tantry US, Marcucci R, Blindt R, Angiolillo DJ, Becker R, Bhatt DL, Cattaneo M, Collet JP, Cuisset T, Gachet C, Montalescot G, Jennings LK, Kereiakes D, Sibbing D, Trenk D, Van Werkum JW, Paganelli F, Price MJ, Waksman R, Gurbel PA. Consensus and future directions on the definition of high on-treatment platelet reactivity to adenosine diphosphate. J Am Coll Cardiol. 2010 Sep 14; 56(12):919-33. 143. Goyal A, Bhatt DL, Steg PG, Gersh BJ, Alberts MJ, Ohman EM, Corbalán R, Eagle KA, Gaxiola E, Gao R, Goto S, D'Agostino RB, Califf RM, Smith SC, Wilson PW. Attained educational level and incident atherothrombotic events in low- and middle-income compared with high-income countries. Circulation. 2010 Sep 21; 122(12):1167-75. 144. Boden WE, Cherr GS, Eagle KA, Cannon CP, Califf RM, Hirsch AT, Alberts MJ, Criqui M, Creager MA, Massaro JM, D'Agostino RB, Steg PG, Bhatt DL. Prior cardiovascular interventions are not associated with worsened clinical outcomes in patients with symptomatic atherothrombosis. Crit Pathw Cardiol. 2010 Sep; 9(3):116-25. 145. Kar S, Krishnaswamy A, Shishehbor MH, Cam A, Tuzcu EM, Bhatt DL, Bajzer C, Kapadia SR. Safety and efficacy of carotid stenting in individuals with concomitant severe carotid and aortic stenosis. EuroIntervention. 2010 Sep; 6(4):492-7. 146. Bhatt DL. Acute coronary syndrome update for hospitalists. J Hosp Med. 2010 Sep; 5 Suppl 4:S15-21. 147. Bangalore S, Bhatt DL, Röther J, Alberts MJ, Thornton J, Wolski K, Goto S, Hirsch AT, Smith SC, Aichner FT, Topakian R, Cannon CP, Steg PG. Late outcomes after carotid artery stenting versus carotid endarterectomy: insights from a propensity-matched analysis of the Reduction of Atherothrombosis for Continued Health (REACH) Registry. Circulation. 2010 Sep 14; 122(11):1091-100. 148. Goto S, Ogawa H, Takeuchi M, Flather MD, Bhatt DL. Double-blind, placebo-controlled Phase II studies of the protease-activated receptor 1 antagonist E5555 (atopaxar) in Japanese patients with acute coronary syndrome or high-risk coronary artery disease. Eur Heart J. 2010 Nov; 31(21):2601-13. 149. Bhatt DL, Eagle KA, Ohman EM, Hirsch AT, Goto S, Mahoney EM, Wilson PW, Alberts MJ, D'Agostino R, Liau CS, Mas JL, Röther J, Smith SC, Salette G, Contant CF, Massaro JM, Steg PG. Comparative determinants of 4-year cardiovascular event rates in stable outpatients at risk of or with atherothrombosis. JAMA. 2010 Sep 22; 304(12):1350-7. 150. Paré G, Mehta SR, Yusuf S, Anand SS, Connolly SJ, Hirsh J, Simonsen K, Bhatt DL, Fox KA, Eikelboom JW. Effects of CYP2C19 genotype on outcomes of clopidogrel treatment. N Engl J Med. 2010 Oct 28; 363(18):1704-14. 151. Kumbhani DJ, Bhatt DL. Platelet activation: yet another strike against routine TRANSFUSION. Eur Heart J. 2010 Nov; 31(22):2712-4. 152. Topol EJ, Bousser MG, Fox KA, Creager MA, Despres JP, Easton JD, Hamm CW, Montalescot G, Steg PG, Pearson TA, Cohen E, Gaudin C, Job B, Murphy JH, Bhatt DL. Rimonabant for prevention of cardiovascular events (CRESCENDO): a randomised, multicentre, placebo-controlled trial. Lancet. 2010 Aug 14; 376(9740):517-23. 153. Suárez C, Zeymer U, Limbourg T, Baumgartner I, Cacoub P, Poldermans D, Röther J, Bhatt DL, Steg PG. Influence of polyvascular disease on cardiovascular event rates. Insights from the REACH Registry. Vasc Med. 2010 Aug; 15(4):259-65. 154. Beygui F, Silvain J, Pena A, Bellemain-Appaix A, Collet JP, Drexler H, Bhatt D, Vicaut E, Montalescot G. Usefulness of biomarker strategy to improve GRACE score's prediction performance in patients with non-ST-segment elevation acute coronary syndrome and low event rates. Am J Cardiol. 2010 Sep 1; 106(5):650-8. 155. Depta JP, Bhatt DL. Atherothrombosis and atrial fibrillation: Important and often overlapping clinical syndromes. Thromb Haemost. 2010 Oct; 104(4):657-63. 156. Gaxiola E, Eng-Ceceña L, Ortiz-Galván F, Llamas-López L, Rangel-Guerra R, Alcocer-Gamba MA, Bhatt DL, Gabriel Steg P. Assessment of atherothrombosis and its treatment in Mexico: first-year data of the REACH Registry. Clin Cardiol. 2010 Jul; 33(7):445-51. 157. Leonardi S, Rao SV, Harrington RA, Bhatt DL, Gibson CM, Roe MT, Kochman J, Huber K, Zeymer U, Madan M, Gretler DD, McClure MW, Paynter GE, Thompson V, Welsh RC. Rationale and design of the randomized, double-blind trial testing INtraveNous and Oral administration of elinogrel, a selective and reversible P2Y(12)-receptor inhibitor, versus clopidogrel to eVAluate Tolerability and Efficacy in nonurgent Percutaneous Coronary Interventions patients (INNOVATE-PCI). Am Heart J. 2010 Jul; 160(1):65-72. 158. Hankey GJ, Hacke W, Easton JD, Johnston SC, Mas JL, Brennan DM, Bhatt DL, Fox KA, Topol EJ. Effect of clopidogrel on the rate and functional severity of stroke among high vascular risk patients: a prespecified substudy of the Clopidogrel for High Atherothrombotic Risk and Ischemic Stabilization, Management and Avoidance (CHARISMA) trial. Stroke. 2010 Aug; 41(8):1679-83. 159. Bhatt DL. Advancing the care of cardiac patients using registry data: going where randomized clinical trials dare not. JAMA. 2010 Jun 2; 303(21):2188-9. 160. Berger PB, Bhatt DL, Fuster V, Steg PG, Fox KA, Shao M, Brennan DM, Hacke W, Montalescot G, Steinhubl SR, Topol EJ. Bleeding complications with dual antiplatelet therapy among patients with stable vascular disease or risk factors for vascular disease: results from the Clopidogrel for High Atherothrombotic Risk and Ischemic Stabilization, Management, and Avoidance (CHARISMA) trial. Circulation. 2010 Jun 15; 121(23):2575-83. 161. Desai NR, Bhatt DL. The state of periprocedural antiplatelet therapy after recent trials. JACC Cardiovasc Interv. 2010 Jun; 3(6):571-83. 162. Geisler T, Gawaz M, Steinhubl SR, Bhatt DL, Storey RF, Flather M. Current strategies in antiplatelet therapy--does identification of risk and adjustment of therapy contribute to more effective, personalized medicine in cardiovascular disease? Pharmacol Ther. 2010 Aug; 127(2):95-107. 163. Boden WE, Flather MD, Bhatt DL. Role of dual antiplatelet therapy in symptomatic patients with established vascular disease: putting the CHARISMA trial into therapeutic perspective. Cardiovasc Drugs Ther. 2010 Jun; 24(3):207-16. 164. Kolandaivelu K, Bhatt DL. Overcoming 'resistance' to antiplatelet therapy: targeting the issue of nonadherence. Nat Rev Cardiol. 2010 Aug; 7(8):461-7. 165. Kashyap SR, Bhatt DL, Schauer PR. Bariatric surgery vs. advanced practice medical management in the treatment of type 2 diabetes mellitus: rationale and design of the Surgical Therapy And Medications Potentially Eradicate Diabetes Efficiently trial (STAMPEDE). Diabetes Obes Metab. 2010 May; 12(5):452-4. 166. Glauser J, Emerman CL, Bhatt DL, Peacock WF. Platelet aspirin resistance in ED patients with suspected acute coronary syndrome. Am J Emerg Med. 2010 May; 28(4):440-4. 167. Winkel TA, Hoeks SE, Schouten O, Zeymer U, Limbourg T, Baumgartner I, Bhatt DL, Steg PG, Goto S, Röther J, Cacoub PP, Verhagen HJ, Bax JJ, Poldermans D. Prognosis of atrial fibrillation in patients with symptomatic peripheral arterial disease: data from the REduction of Atherothrombosis for Continued Health (REACH) Registry. Eur J Vasc Endovasc Surg. 2010 Jul; 40(1):9-16. 168. Dauerman HL, Bhatt DL, Gretler DD, French PA, Smyth SS, Becker RC. Bridging the gap between clinical trials of antiplatelet therapies and applications among elderly patients. Am Heart J. 2010 Apr; 159(4):508-517.e1. 169. Ademi Z, Walls HL, Peeters A, Liew D, Hollingsworth B, Stevenson C, Steg PG, Bhatt DL, Reid CM. Economic implications of obesity among people with atherothrombotic disease. Int J Obes (Lond). 2010 Aug; 34(8):1284-92. 170. Krempf M, Parhofer KG, Steg PG, Bhatt DL, Ohman EM, Röther J, Goto S, Pasquet B, Wilson PW. Cardiovascular event rates in diabetic and nondiabetic individuals with and without established atherothrombosis (from the REduction of Atherothrombosis for Continued Health [REACH] Registry). Am J Cardiol. 2010 Mar 1; 105(5):667-71. 171. Arepally G, Bauer KA, Bhatt DL, Merli GJ, Naccarelli GV, Carter RD, Karcher RB, Berry CA, Keaton KL, Stowell SA. The use of antithrombotic therapies in the prevention and treatment of arterial and venous thrombosis: a survey of current knowledge and practice supporting the need for clinical education. Crit Pathw Cardiol. 2010 Mar; 9(1):41-8. 172. Sakhuja R, Yeh RW, Bhatt DL. Antiplatelet agents in acute coronary syndromes. Curr Probl Cardiol. 2010 Mar; 35(3):123-70. 173. Ducrocq G, Wallace JS, Baron G, Ravaud P, Alberts MJ, Wilson PW, Ohman EM, Brennan DM, D'Agostino RB, Bhatt DL, Steg PG. Risk score to predict serious bleeding in stable outpatients with or at risk of atherothrombosis. Eur Heart J. 2010 May; 31(10):1257-65. 174. Depta JP, Bhatt DL. Omeprazole and clopidogrel: Should clinicians be worried? Cleve Clin J Med. 2010 Feb; 77(2):113-6. 175. Bhatt DL. Controversies in non-ST-elevation acute coronary syndromes and percutaneous coronary interventions. Cleve Clin J Med. 2010 Feb; 77(2):101-9. 176. Cannon CP, Rhee KE, Califf RM, Boden WE, Hirsch AT, Alberts MJ, Cable G, Shao M, Ohman EM, Steg PG, Eagle KA, Bhatt DL. Current use of aspirin and antithrombotic agents in the United States among outpatients with atherothrombotic disease (from the REduction of Atherothrombosis for Continued Health [REACH] Registry). Am J Cardiol. 2010 Feb 15; 105(4):445-52. 177. Ademi Z, Liew D, Hollingsworth B, Steg PG, Bhatt DL, Reid CM. Predictors of annual pharmaceutical costs in Australia for community-based individuals with, or at risk of, cardiovascular disease: analysis of Australian data from the REACH registry. Am J Cardiovasc Drugs. 2010; 10(2):85-94. 178. Ademi Z, Liew D, Hollingsworth B, Wolfe R, Steg GP, Bhatt DL, Reid CM. The economic implications of treating atherothrombotic disease in Australia, from the government perspective. Clin Ther. 2010 Jan; 32(1):119-32; discussion 106-7. 179. Harrington RA, Stone GW, McNulty S, White HD, Lincoff AM, Gibson CM, Pollack CV, Montalescot G, Mahaffey KW, Kleiman NS, Goodman SG, Amine M, Angiolillo DJ, Becker RC, Chew DP, French WJ, Leisch F, Parikh KH, Skerjanec S, Bhatt DL. Platelet inhibition with cangrelor in patients undergoing PCI. N Engl J Med. 2009 Dec 10; 361(24):2318-29. 180. Bhatt DL, Lincoff AM, Gibson CM, Stone GW, McNulty S, Montalescot G, Kleiman NS, Goodman SG, White HD, Mahaffey KW, Pollack CV, Manoukian SV, Widimsky P, Chew DP, Cura F, Manukov I, Tousek F, Jafar MZ, Arneja J, Skerjanec S, Harrington RA. Intravenous platelet blockade with cangrelor during PCI. N Engl J Med. 2009 Dec 10; 361(24):2330-41. 181. Meadows TA, Bhatt DL, Hirsch AT, Creager MA, Califf RM, Ohman EM, Cannon CP, Eagle KA, Alberts MJ, Goto S, Smith SC, Wilson PW, Watson KE, Steg PG. Ethnic differences in the prevalence and treatment of cardiovascular risk factors in US outpatients with peripheral arterial disease: insights from the reduction of atherothrombosis for continued health (REACH) registry. Am Heart J. 2009 Dec; 158(6):1038-45. 182. Bhatt DL. Antiplatelet therapy: Ticagrelor in ACS-what does PLATO teach us? Nat Rev Cardiol. 2009 Dec; 6(12):737-8. 183. Kumbhani DJ, Cannon CP, Fonarow GC, Liang L, Askari AT, Peacock WF, Peterson ED, Bhatt DL. Association of hospital primary angioplasty volume in ST-segment elevation myocardial infarction with quality and outcomes. JAMA. 2009 Nov 25; 302(20):2207-13. 184. Mechtouff L, Touzé E, Steg PG, Ohman EM, Goto S, Hirsch AT, Röther J, Aichner FT, Weimar C, Bhatt DL, Alberts MJ, Mas JL. Worse blood pressure control in patients with cerebrovascular or peripheral arterial disease compared with coronary artery disease. J Intern Med. 2010 Jun; 267(6):621-33. 185. Berger JS, Bhatt DL, Steinhubl SR, Shao M, Steg PG, Montalescot G, Hacke W, Fox KA, Lincoff AM, Topol EJ, Berger PB. Smoking, clopidogrel, and mortality in patients with established cardiovascular disease. Circulation. 2009 Dec 8; 120(23):2337-44. 186. Berger JS, Bhatt DL, Cannon CP, Chen Z, Jiang L, Jones JB, Mehta SR, Sabatine MS, Steinhubl SR, Topol EJ, Berger PB. The relative efficacy and safety of clopidogrel in women and men a sex-specific collaborative meta-analysis. J Am Coll Cardiol. 2009 Nov 17; 54(21):1935-45. 187. Depta JP, Cannon CP, Fonarow GC, Zhao X, Peacock WF, Bhatt DL. Patient characteristics associated with the choice of triple antithrombotic therapy in acute coronary syndromes. Am J Cardiol. 2009 Nov 1; 104(9):1171-8. 188. Parhofer KG, Zeymer U, Stark RG, Binz C, Schwertfeger M, Bhatt DL, Steg PG, Röther J. In Germany diabetic patients with coronary artery disease are treated more intensively than diabetic patients with other manifestations of atherothrombosis--results from the REACH registry. Exp Clin Endocrinol Diabetes. 2010 Jan; 118(1):51-6. 189. Uchiyama S, Goto S, Matsumoto M, Nagai R, Origasa H, Yamazaki T, Shigematsu H, Shimada K, Yamada N, Bhatt DL, Steg PG, Ikeda Y. Cardiovascular event rates in patients with cerebrovascular disease and atherothrombosis at other vascular locations: results from 1-year outcomes in the Japanese REACH Registry. J Neurol Sci. 2009 Dec 15; 287(1-2):45-51. 190. Wang TD, Goto S, Bhatt DL, Steg PG, Chan JC, Richard AJ, Liau CS. Ethnic differences in the relationships of anthropometric measures to metabolic risk factors in Asian patients at risk of atherothrombosis: results from the REduction of Atherothrombosis for Continued Health (REACH) Registry. Metabolism. 2010 Mar; 59(3):400-8. 191. Shishehbor MH, Hawi R, Singh IM, Tuzcu EM, Bhatt DL, Ellis SG, Kapadia SR. Drug-eluting versus bare-metal stents for treating saphenous vein grafts. Am Heart J. 2009 Oct; 158(4):637-43. 192. Kumar A, Fonarow GC, Eagle KA, Hirsch AT, Califf RM, Alberts MJ, Boden WE, Steg PG, Shao M, Bhatt DL, Cannon CP. Regional and practice variation in adherence to guideline recommendations for secondary and primary prevention among outpatients with atherothrombosis or risk factors in the United States: a report from the REACH Registry. Crit Pathw Cardiol. 2009 Sep; 8(3):104-11. 193. Wang TY, Newby LK, Chen AY, Mulgund J, Roe MT, Sonel AF, Bhatt DL, DeLong ER, Ohman EM, Gibler WB, Peterson ED. Hypercholesterolemia paradox in relation to mortality in acute coronary syndrome. Clin Cardiol. 2009 Sep; 32(9):E22-8. 194. Alberts MJ, Bhatt DL, Mas JL, Ohman EM, Hirsch AT, Röther J, Salette G, Goto S, Smith SC, Liau CS, Wilson PW, Steg PG. Three-year follow-up and event rates in the international REduction of Atherothrombosis for Continued Health Registry. Eur Heart J. 2009 Oct; 30(19):2318-26. 195. Bhatt DL. Tailoring antiplatelet therapy based on pharmacogenomics: how well do the data fit? JAMA. 2009 Aug 26; 302(8):896-7. 196. Montalescot G, Drexler H, Gallo R, Pearson T, Thoenes M, Bhatt DL. Effect of irbesartan and enalapril in non-ST elevation acute coronary syndrome: results of the randomized, double-blind ARCHIPELAGO study. Eur Heart J. 2009 Nov; 30(22):2733-41. 197. Chu SG, Becker RC, Berger PB, Bhatt DL, Eikelboom JW, Konkle B, Mohler ER, Reilly MP, Berger JS. Mean platelet volume as a predictor of cardiovascular risk: a systematic review and meta-analysis. J Thromb Haemost. 2010 Jan; 8(1):148-56. 198. Lee JY, Bhatt D, Bhatt D, Chung WY, Cooper RL. Furthering pharmacological and physiological assessment of the glutamatergic receptors at the Drosophila neuromuscular junction. Comp Biochem Physiol C Toxicol Pharmacol. 2009 Nov; 150(4):546-57. 199. Brilakis ES, Hernandez AF, Dai D, Peterson ED, Banerjee S, Fonarow GC, Cannon CP, Bhatt DL. Quality of care for acute coronary syndrome patients with known atherosclerotic disease: results from the Get With the Guidelines Program. Circulation. 2009 Aug 18; 120(7):560-7. 200. Desai NR, Bhatt DL. Evaluating percutaneous support for cardiogenic shock: data shock and sticker shock. Eur Heart J. 2009 Sep; 30(17):2073-5. 201. Bhatt DL. Prasugrel in clinical practice. N Engl J Med. 2009 Sep 3; 361(10):940-2. 202. Singh J, Bhatt DL. Refining the role of antiplatelet therapy for atrial fibrillation. Curr Cardiol Rep. 2009 Jul; 11(4):239-40. 203. Serebruany VL, Kogushi M, Dastros-Pitei D, Flather M, Bhatt DL. The in-vitro effects of E5555, a protease-activated receptor (PAR)-1 antagonist, on platelet biomarkers in healthy volunteers and patients with coronary artery disease. Thromb Haemost. 2009 Jul; 102(1):111-9. 204. Dumaine RL, Montalescot G, Steg PG, Ohman EM, Eagle K, Bhatt DL. Renal function, atherothrombosis extent, and outcomes in high-risk patients. Am Heart J. 2009 Jul; 158(1):141-148.e1. 205. Chhatriwalla AK, Cam A, Unzek S, Bhatt DL, Raymond RE, Lincoff AM, Whitlow PL, Ellis SG, Tuzcu EM, Kapadia SR. Drug-eluting stent fracture and acute coronary syndrome. Cardiovasc Revasc Med. 2009 Jul-Sep; 10(3):166-71. 206. Collet JP, Montalescot G, Steg PG, Steinhubl SR, Fox KA, Hu TF, Johnston SC, Hamm CW, Bhatt DL, Topol EJ. Clinical outcomes according to permanent discontinuation of clopidogrel or placebo in the CHARISMA trial. Arch Cardiovasc Dis. 2009 Jun-Jul; 102(6-7):485-96. 207. Dhoble A, Patel MB, Abdelmoneim SS, Puttarajappa C, Abela GS, Bhatt DL, Thakur RK. Relation of porphyria to atrial fibrillation. Am J Cardiol. 2009 Aug 1; 104(3):373-6. 208. Eagle KA, Hirsch AT, Califf RM, Alberts MJ, Steg PG, Cannon CP, Brennan DM, Bhatt DL. Cardiovascular ischemic event rates in outpatients with symptomatic atherothrombosis or risk factors in the united states: insights from the REACH Registry. Crit Pathw Cardiol. 2009 Jun; 8(2):91-7. 209. Roukoz H, Bavry AA, Sarkees ML, Mood GR, Kumbhani DJ, Rabbat MG, Bhatt DL. Comprehensive meta-analysis on drug-eluting stents versus bare-metal stents during extended follow-up. Am J Med. 2009 Jun; 122(6):581.e1-10. 210. Alexander JH, Becker RC, Bhatt DL, Cools F, Crea F, Dellborg M, Fox KA, Goodman SG, Harrington RA, Huber K, Husted S, Lewis BS, Lopez-Sendon J, Mohan P, Montalescot G, Ruda M, Ruzyllo W, Verheugt F, Wallentin L. Apixaban, an oral, direct, selective factor Xa inhibitor, in combination with antiplatelet therapy after acute coronary syndrome: results of the Apixaban for Prevention of Acute Ischemic and Safety Events (APPRAISE) trial. Circulation. 2009 Jun 9; 119(22):2877-85. 211. Belkin M, Bhatt DL. Carotid stenting in the elderly: is 80 the new 60? Circulation. 2009 May 5; 119(17):2302-4. 212. Dasgupta A, Steinhubl SR, Bhatt DL, Berger PB, Shao M, Mak KH, Fox KA, Montalescot G, Weber MA, Haffner SM, Dimas AP, Steg PG, Topol EJ. Clinical outcomes of patients with diabetic nephropathy randomized to clopidogrel plus aspirin versus aspirin alone (a post hoc analysis of the clopidogrel for high atherothrombotic risk and ischemic stabilization, management, and avoidance [CHARISMA] trial). Am J Cardiol. 2009 May 15; 103(10):1359-63. 213. Bhatt DL, Kottke-Marchant K, Alexander JH, Peacock WF, Sabatine MS. Platelet response in practice: Applying new insights and tools for testing and treatment. Cleve Clin J Med. 2009 Apr; 76 Suppl 1:S24-32. 214. Shishehbor MH, Filby SJ, Chhatriwalla AK, Christofferson RD, Jain A, Kapadia SR, Lincoff AM, Bhatt DL, Ellis SG. Impact of drug-eluting versus bare-metal stents on mortality in patients with anemia. JACC Cardiovasc Interv. 2009 Apr; 2(4):329-36. 215. Bhatt DL, Peterson ED, Harrington RA, Ou FS, Cannon CP, Gibson CM, Kleiman NS, Brindis RG, Peacock WF, Brener SJ, Menon V, Smith SC, Pollack CV, Gibler WB, Ohman EM, Roe MT. Prior polyvascular disease: risk factor for adverse ischaemic outcomes in acute coronary syndromes. Eur Heart J. 2009 May; 30(10):1195-202. 216. Sakhuja R, Bhatt DL. Getting real with drug-eluting stents: 5-year follow up of a real-world cohort. Am Heart J. 2009 May; 157(5):802-4. 217. Aichner FT, Topakian R, Alberts MJ, Bhatt DL, Haring HP, Hill MD, Montalescot G, Goto S, Touzé E, Mas JL, Steg PG, Röther J. High cardiovascular event rates in patients with asymptomatic carotid stenosis: the REACH Registry. Eur J Neurol. 2009 Aug; 16(8):902-8. 218. Steinhubl SR, Bhatt DL, Brennan DM, Montalescot G, Hankey GJ, Eikelboom JW, Berger PB, Topol EJ. Aspirin to prevent cardiovascular disease: the association of aspirin dose and clopidogrel with thrombosis and bleeding. Ann Intern Med. 2009 Mar 17; 150(6):379-86. 219. Chen J, Bhatt DL, Dunn ES, Shi C, Caro JJ, Mahoney EM, Gabriel S, Jackson JD, Topol EJ, Cohen DJ. Cost-effectiveness of clopidogrel plus aspirin versus aspirin alone for secondary prevention of cardiovascular events: results from the CHARISMA trial. Value Health. 2009 Sep; 12(6):872-9. 220. Mak KH, Bhatt DL, Shao M, Haffner SM, Hamm CW, Hankey GJ, Johnston SC, Montalescot G, Steg PG, Steinhubl SR, Fox KA, Topol EJ. The influence of body mass index on mortality and bleeding among patients with or at high-risk of atherothrombotic disease. Eur Heart J. 2009 Apr; 30(7):857-65. 221. Mehta C, Gao P, Bhatt DL, Harrington RA, Skerjanec S, Ware JH. Optimizing trial design: sequential, adaptive, and enrichment strategies. Circulation. 2009 Feb 3; 119(4):597-605. 222. Bhatt DL. Role of antiplatelet therapy across the spectrum of patients with coronary artery disease. Am J Cardiol. 2009 Feb 2; 103(3 Suppl):11A-19A. 223. Angiolillo DJ, Bhatt DL, Gurbel PA, Jennings LK. Advances in antiplatelet therapy: agents in clinical development. Am J Cardiol. 2009 Feb 2; 103(3 Suppl):40A-51A. 224. Brener SJ, Bhatt DL. The pain and the gain of treating patients with acute coronary syndromes-can the two be separated? Am Heart J. 2009 Mar; 157(3):399-401. 225. Sakhuja R, Keebler M, Lai TS, McLaughlin Gavin C, Thakur R, Bhatt DL. Meta-analysis of mortality in dialysis patients with an implantable cardioverter defibrillator. Am J Cardiol. 2009 Mar 1; 103(5):735-41. 226. Cacoub PP, Bhatt DL, Steg PG, Topol EJ, Creager MA. Patients with peripheral arterial disease in the CHARISMA trial. Eur Heart J. 2009 Jan; 30(2):192-201. 227. Ademi Z, Liew D, Chew D, Conner G, Shiel L, Nelson M, Soman A, Steg G, Bhatt DL, Reid C. Drug treatment and cost of cardiovascular disease in Australia. Cardiovasc Ther. 2009; 27(3):164-72. 228. Bainey KR, Bhatt DL. Acute pericarditis: appendicitis of the heart? Mayo Clin Proc. 2009; 84(1):5-6. 229. Sarkees ML, Bavry AA, Galla JM, Bhatt DL. Bare metal stent thrombosis 13 years after implantation. Cardiovasc Revasc Med. 2009 Jan-Mar; 10(1):58-9. 230. Chhatriwalla AK, Bhatt DL. Should dual antiplatelet therapy after drug-eluting stents be continued for more than 1 year?: Dual antiplatelet therapy after drug-eluting stents should be continued for more than one year and preferably indefinitely. Circ Cardiovasc Interv. 2008 Dec; 1(3):217-25. 231. Bhatt DL. Resisting the temptation to oversimplify antiplatelet resistance. JACC Cardiovasc Interv. 2008 Dec; 1(6):660-2. 232. Weimar C, Diener HC, Alberts MJ, Steg PG, Bhatt DL, Wilson PW, Mas JL, Röther J. The Essen stroke risk score predicts recurrent cardiovascular events: a validation within the REduction of Atherothrombosis for Continued Health (REACH) registry. Stroke. 2009 Feb; 40(2):350-4. 233. Mehta RH, Bhatt DL, Steg PG, Goto S, Hirsch AT, Liau CS, Röther J, Wilson PW, Richard AJ, Eagle KA, Ohman EM. Modifiable risk factors control and its relationship with 1 year outcomes after coronary artery bypass surgery: insights from the REACH registry. Eur Heart J. 2008 Dec; 29(24):3052-60. 234. Mak KH, Bhatt DL, Shao M, Hankey GJ, Easton JD, Fox KA, Topol EJ. Ethnic variation in adverse cardiovascular outcomes and bleeding complications in the Clopidogrel for High Atherothrombotic Risk and Ischemic Stabilization, Management, and Avoidance (CHARISMA) study. Am Heart J. 2009 Apr; 157(4):658-65. 235. Cacoub PP, Abola MT, Baumgartner I, Bhatt DL, Creager MA, Liau CS, Goto S, Röther J, Steg PG, Hirsch AT. Cardiovascular risk factor control and outcomes in peripheral artery disease patients in the Reduction of Atherothrombosis for Continued Health (REACH) Registry. Atherosclerosis. 2009 Jun; 204(2):e86-92. 236. Bhatt DL, Scheiman J, Abraham NS, Antman EM, Chan FK, Furberg CD, Johnson DA, Mahaffey KW, Quigley EM, Harrington RA, Bates ER, Bridges CR, Eisenberg MJ, Ferrari VA, Hlatky MA, Kaul S, Lindner JR, Moliterno DJ, Mukherjee D, Schofield RS, Rosenson RS, Stein JH, Weitz HH, Wesley DJ. ACCF/ACG/AHA 2008 expert consensus document on reducing the gastrointestinal risks of antiplatelet therapy and NSAID use: a report of the American College of Cardiology Foundation Task Force on Clinical Expert Consensus Documents. J Am Coll Cardiol. 2008 Oct 28; 52(18):1502-17. 237. Eikelboom JW, Hankey GJ, Thom J, Bhatt DL, Steg PG, Montalescot G, Johnston SC, Steinhubl SR, Mak KH, Easton JD, Hamm C, Hu T, Fox KA, Topol EJ. Incomplete inhibition of thromboxane biosynthesis by acetylsalicylic acid: determinants and effect on cardiovascular risk. Circulation. 2008 Oct 21; 118(17):1705-12. 238. Bhatt DL, Scheiman J, Abraham NS, Antman EM, Chan FK, Furberg CD, Johnson DA, Mahaffey KW, Quigley EM. ACCF/ACG/AHA 2008 expert consensus document on reducing the gastrointestinal risks of antiplatelet therapy and NSAID use: a report of the American College of Cardiology Foundation Task Force on Clinical Expert Consensus Documents. Circulation. 2008 Oct 28; 118(18):1894-909. 239. Bhatt DL, Scheiman J, Abraham NS, Antman EM, Chan FK, Furberg CD, Johnson DA, Mahaffey KW, Quigley EM, Harrington RA, Bates ER, Bridges CR, Eisenberg MJ, Ferrari VA, Hlatky MA, Kaul S, Lindner JR, Moliterno DJ, Mukherjee D, Schofield RS, Rosenson RS, Stein JH, Weitz HH, Wesley DJ. ACCF/ACG/AHA 2008 expert consensus document on reducing the gastrointestinal risks of antiplatelet therapy and NSAID use. Am J Gastroenterol. 2008 Nov; 103(11):2890-907. 240. Bhatt DL. Prasugrel versus clopidogrel in acute coronary syndrome patients undergoing percutaneous coronary intervention. Curr Atheroscler Rep. 2008 Oct; 10(5):367-8. 241. Bhatt DL. Is it time to switch to radial access? J Invasive Cardiol. 2008 Oct; 20(10):A6, A8, A14. 242. Bavry AA, Kumbhani DJ, Bhatt DL. Role of adjunctive thrombectomy and embolic protection devices in acute myocardial infarction: a comprehensive meta-analysis of randomized trials. Eur Heart J. 2008 Dec; 29(24):2989-3001. 243. Shishehbor MH, Goel SS, Kapadia SR, Bhatt DL, Kelly P, Raymond RE, Galla JM, Brener SJ, Whitlow PL, Ellis SG. Long-term impact of drug-eluting stents versus bare-metal stents on all-cause mortality. J Am Coll Cardiol. 2008 Sep 23; 52(13):1041-8. 244. Bhatt DL. What makes platelets angry: diabetes, fibrinogen, obesity, and impaired response to antiplatelet therapy? J Am Coll Cardiol. 2008 Sep 23; 52(13):1060-1. 245. Goto S, Bhatt DL, Röther J, Alberts M, Hill MD, Ikeda Y, Uchiyama S, D'Agostino R, Ohman EM, Liau CS, Hirsch AT, Mas JL, Wilson PW, Corbalán R, Aichner F, Steg PG. Prevalence, clinical profile, and cardiovascular outcomes of atrial fibrillation patients with atherothrombosis. Am Heart J. 2008 Nov; 156(5):855-63, 863.e2. 246. Mahoney EM, Wang K, Cohen DJ, Hirsch AT, Alberts MJ, Eagle K, Mosse F, Jackson JD, Steg PG, Bhatt DL. One-year costs in patients with a history of or at risk for atherothrombosis in the United States. Circ Cardiovasc Qual Outcomes. 2008 Sep; 1(1):38-45. 247. Helton TJ, Bavry AA, Rajagopal V, Anderson RD, Yadav JS, Bhatt DL. The optimal treatment of carotid atherosclerosis: a 2008 update and literature review. Postgrad Med. 2008 Sep; 120(3):103-12. 248. Pottenger BC, Diercks DB, Bhatt DL. Regionalization of care for ST-segment elevation myocardial infarction: is it too soon? Ann Emerg Med. 2008 Dec; 52(6):677-685. 249. Mood GR, Bavry AA, Bhatt DL. Clopidogrel and coronary stents: risks and benefits. Curr Atheroscler Rep. 2008 Aug; 10(4):303-8. 250. Baumgartner I, Hirsch AT, Abola MT, Cacoub PP, Poldermans D, Steg PG, Creager MA, Bhatt DL. Cardiovascular risk profile and outcome of patients with abdominal aortic aneurysm in out-patients with atherothrombosis: data from the Reduction of Atherothrombosis for Continued Health (REACH) Registry. J Vasc Surg. 2008 Oct; 48(4):808-14. 251. Steinberg BA, Bhatt DL, Mehta S, Poole-Wilson PA, O'Hagan P, Montalescot G, Ballantyne CM, Cannon CP. Nine-year trends in achievement of risk factor goals in the US and European outpatients with cardiovascular disease. Am Heart J. 2008 Oct; 156(4):719-27. 252. Mehran R, Brodie B, Cox DA, Grines CL, Rutherford B, Bhatt DL, Dangas G, Feit F, Ohman EM, Parise H, Fahy M, Lansky AJ, Stone GW. The Harmonizing Outcomes with RevasculariZatiON and Stents in Acute Myocardial Infarction (HORIZONS-AMI) Trial: study design and rationale. Am Heart J. 2008 Jul; 156(1):44-56. 253. Bavry AA, Bhatt DL. Appropriate use of drug-eluting stents: balancing the reduction in restenosis with the concern of late thrombosis. Lancet. 2008 Jun 21; 371(9630):2134-43. 254. Shishehbor MH, Amini R, Oliveria LP, Singh IM, Kelly P, Bhatt DL, Kapadia SR, Ellis SG, Whitlow PL, Brener SJ. Comparison of drug-eluting stents versus bare-metal stents for treating ST-segment elevation myocardial infarction. JACC Cardiovasc Interv. 2008 Jun; 1(3):227-32. 255. Bhatt DL. Anti-inflammatory agents and antioxidants as a possible "third great wave" in cardiovascular secondary prevention. Am J Cardiol. 2008 May 22; 101(10A):4D-13D. 256. Bhatt DL, Pashkow FJ. Introduction. Oxidative stress and heart disease. Am J Cardiol. 2008 May 22; 101(10A):1D-2D. 257. Madhwal S, Rajagopal V, Bhatt DL, Bajzer CT, Whitlow P, Kapadia SR. Predictors of difficult carotid stenting as determined by aortic arch angiography. J Invasive Cardiol. 2008 May; 20(5):200-4. 258. Chhatriwalla AK, Bhatt DL. Breaking with tradition: is diagnostic angiography really necessary before primary PCI? J Invasive Cardiol. 2008 May; 20(5):229-30. 259. Nissen SE, Nicholls SJ, Wolski K, Rodés-Cabau J, Cannon CP, Deanfield JE, Després JP, Kastelein JJ, Steinhubl SR, Kapadia S, Yasin M, Ruzyllo W, Gaudin C, Job B, Hu B, Bhatt DL, Lincoff AM, Tuzcu EM. Effect of rimonabant on progression of atherosclerosis in patients with abdominal obesity and coronary artery disease: the STRADIVARIUS randomized controlled trial. JAMA. 2008 Apr 2; 299(13):1547-60. 260. Bakhru MR, Bhatt DL. Interpreting the CHARISMA study. What is the role of dual antiplatelet therapy with clopidogrel and aspirin? Cleve Clin J Med. 2008 Apr; 75(4):289-95. 261. Bavry AA, Raymond RE, Bhatt DL, Chambers CE, DeNardo AJ, Hermiller JB, Myers PR, Pitts DE, Scott JA, Savader SJ, Steinhubl S. Efficacy of a novel procedure sheath and closure device during diagnostic catheterization: the multicenter randomized clinical trial of the FISH device. J Invasive Cardiol. 2008 Apr; 20(4):152-6. 262. Bhatt DL. Is prasugrel superior to clopidogrel for patients with acute coronary syndromes undergoing PCI? Nat Clin Pract Cardiovasc Med. 2008 May; 5(5):252-3. 263. Röther J, Alberts MJ, Touzé E, Mas JL, Hill MD, Michel P, Bhatt DL, Aichner FT, Goto S, Matsumoto M, Ohman EM, Okada Y, Uchiyama S, D'Agostino R, Hirsch AT, Wilson PW, Steg PG. Risk factor profile and management of cerebrovascular patients in the REACH Registry. Cerebrovasc Dis. 2008; 25(4):366-74. 264. Shishehbor MH, Amini R, Raymond RE, Bavry AA, Brener SJ, Kapadia SR, Whitlow PL, Ellis SG, Bhatt DL. Safety and efficacy of overlapping sirolimus-eluting versus paclitaxel-eluting stents. Am Heart J. 2008 Jun; 155(6):1075-80. 265. Braunwald E, Angiolillo D, Bates E, Berger PB, Bhatt D, Cannon CP, Furman MI, Gurbel P, Michelson AD, Peterson E, Wiviott S. Antiplatelet strategies: evaluating their current role in the setting of acute coronary syndromes. Clin Cardiol. 2008 Mar; 31(3 Suppl 1):I2-9. 266. Braunwald E, Angiolillo D, Bates E, Berger PB, Bhatt D, Cannon CP, Furman MI, Gurbel P, Michelson AD, Peterson E, Wiviott S. Antiplatelet therapy and platelet function testing. Introduction. Clin Cardiol. 2008 Mar; 31(3 Suppl 1):I1. 267. Braunwald E, Angiolillo D, Bates E, Berger PB, Bhatt D, Cannon CP, Furman MI, Gurbel P, Michelson AD, Peterson E, Wiviott S. The problem of persistent platelet activation in acute coronary syndromes and following percutaneous coronary intervention. Clin Cardiol. 2008 Mar; 31(3 Suppl 1):I17-20. 268. Braunwald E, Angiolillo D, Bates E, Berger PB, Bhatt D, Cannon CP, Furman MI, Gurbel P, Michelson AD, Peterson E, Wiviott S. Antiplatelet therapy and platelet function testing. Clin Cardiol. 2008 Mar; 31(3 Suppl 1):I36. 269. Braunwald E, Angiolillo D, Bates E, Berger PB, Bhatt D, Cannon CP, Furman MI, Gurbel P, Michelson AD, Peterson E, Wiviott S. Investigating the mechanisms of hyporesponse to antiplatelet approaches. Clin Cardiol. 2008 Mar; 31(3 Suppl 1):I21-7. 270. Bhatt DL. Percutaneous coronary intervention in nonagenarians: age before beauty? Catheter Cardiovasc Interv. 2008 Mar 1; 71(4):531-2. 271. Braunwald E, Angiolillo D, Bates E, Berger PB, Bhatt D, Cannon CP, Furman MI, Gurbel P, Michelson AD, Peterson E, Wiviott S. Clinical considerations with the use of antiplatelet therapy in patients undergoing percutaneous coronary intervention. Clin Cardiol. 2008 Mar; 31(3 Suppl 1):I28-35. 272. Braunwald E, Angiolillo D, Bates E, Berger PB, Bhatt D, Cannon CP, Furman MI, Gurbel P, Michelson AD, Peterson E, Wiviott S. Assessing the current role of platelet function testing. Clin Cardiol. 2008 Mar; 31(3 Suppl 1):I10-6. 273. Hart RG, Bhatt DL, Hacke W, Fox KA, Hankey GJ, Berger PB, Hu T, Topol EJ. Clopidogrel and aspirin versus aspirin alone for the prevention of stroke in patients with a history of atrial fibrillation: subgroup analysis of the CHARISMA randomized trial. Cerebrovasc Dis. 2008; 25(4):344-7. 274. Kumbhani DJ, Bavry AA, Kamdar AR, Helton TJ, Bhatt DL. The effect of drug-eluting stents on intermediate angiographic and clinical outcomes in diabetic patients: insights from randomized clinical trials. Am Heart J. 2008 Apr; 155(4):640-7. 275. Shishehbor MH, Bhatt DL. Treating patients with non-STEMI: stent the culprit artery only or address all lesions? Curr Treat Options Cardiovasc Med. 2008 Feb; 10(1):93-7. 276. Brener SJ, Milford-Beland S, Roe MT, Bhatt DL, Weintraub WS, Brindis RG. Culprit-only or multivessel revascularization in patients with acute coronary syndromes: an American College of Cardiology National Cardiovascular Database Registry report. Am Heart J. 2008 Jan; 155(1):140-6. 277. Peacock WF, Bhatt DL, Diercks D, Amsterdam E, Chandra A, Ohman EM, Brown DF, Januzzi J. Cardiologists' and emergency physicians' perspectives on and knowledge of reperfusion guidelines pertaining to ST-segment-elevation myocardial infarction. Tex Heart Inst J. 2008; 35(2):152-61. 278. Depta JP, Bhatt DL. Aspirin and platelet adenosine diphosphate receptor antagonists in acute coronary syndromes and percutaneous coronary intervention: role in therapy and strategies to overcome resistance. Am J Cardiovasc Drugs. 2008; 8(2):91-112. 279. Novaro GM, Asher CR, Bhatt DL, Moliterno DJ, Harrington RA, Lincoff AM, Newby LK, Tcheng JE, Hsu AP, Pinski SL. Meta-analysis comparing reported frequency of atrial fibrillation after acute coronary syndromes in Asians versus whites. Am J Cardiol. 2008 Feb 15; 101(4):506-9. 280. Bhatt DL. Intensifying platelet inhibition--navigating between Scylla and Charybdis. N Engl J Med. 2007 Nov 15; 357(20):2078-81. 281. Mood GR, Bhatt DL. Clopidogrel and risk for acute coronary events. Curr Atheroscler Rep. 2007 Nov; 9(5):401-8. 282. Brotman DJ, Bakhru M, Saber W, Aneja A, Bhatt DL, Tillan-Martinez K, Jaffer AK. Discontinuation of antiplatelet therapy prior to low-risk noncardiac surgery in patients with drug-eluting stents: a retrospective cohort study. J Hosp Med. 2007 Nov; 2(6):378-84. 283. Medina HM, Bhatt DL. Evolution of anticoagulant and antiplatelet therapy: benefits and risks of contemporary pharmacologic agents and their implications for myonecrosis and bleeding in percutaneous coronary intervention. Clin Cardiol. 2007 Oct; 30(10 Suppl 2):II4-15. 284. Bhatt DL. Interpreting the COURAGE trial. Is medical therapy as good as PCI in stable angina? Two views. Cleve Clin J Med. 2007 Sep; 74(9):618, 620. 285. Bavry AA, Bhatt DL. Drug-eluting stents: dual antiplatelet therapy for every survivor? Circulation. 2007 Aug 14; 116(7):696-9. 286. Wang TH, Bhatt DL, Fox KA, Steinhubl SR, Brennan DM, Hacke W, Mak KH, Pearson TA, Boden WE, Steg PG, Flather MD, Montalescot G, Topol EJ. An analysis of mortality rates with dual-antiplatelet therapy in the primary prevention population of the CHARISMA trial. Eur Heart J. 2007 Sep; 28(18):2200-7. 287. Bavry AA, Bhatt DL. Designing the ideal risk model for acute coronary syndromes--is simple better than complex? Am Heart J. 2007 Aug; 154(2):206-7. 288. Doonan AL, Karha J, Carrigan TP, Bavry AA, Begelman SM, Ellis SG, Yadav J, Bhatt DL. Presence of carotid and peripheral arterial disease in patients with left main disease. Am J Cardiol. 2007 Oct 1; 100(7):1087-9. 289. Saw J, Brennan DM, Steinhubl SR, Bhatt DL, Mak KH, Fox K, Topol EJ. Lack of evidence of a clopidogrel-statin interaction in the CHARISMA trial. J Am Coll Cardiol. 2007 Jul 24; 50(4):291-5. 290. Bhatt DL, Chew DP, Grines C, Mukherjee D, Leesar M, Gilchrist IC, Corbelli JC, Blankenship JC, Eres A, Steinhubl S, Tan WA, Resar JR, AlMahameed A, Abdel-Latif A, Wilson Tang WH, Tang HW, Brennan D, McErlean E, Hazen SL, Topol EJ. Peroxisome proliferator-activated receptor gamma agonists for the Prevention of Adverse events following percutaneous coronary Revascularization--results of the PPAR study. Am Heart J. 2007 Jul; 154(1):137-43. 291. Yamazaki T, Goto S, Shigematsu H, Shimada K, Uchiyama S, Nagai R, Yamada N, Matsumoto M, Origasa H, Bhatt DL, Steg PG, Ikeda Y. Prevalence, awareness and treatment of cardiovascular risk factors in patients at high risk of atherothrombosis in Japan. Circ J. 2007 Jul; 71(7):995-1003. 292. Mood GR, Bavry AA, Roukoz H, Bhatt DL. Meta-analysis of the role of statin therapy in reducing myocardial infarction following elective percutaneous coronary intervention. Am J Cardiol. 2007 Sep 15; 100(6):919-23. 293. Steinberg BA, Ballantyne CM, Bhatt DL, Montalescot G, Mehta S, O'Hagan P, Poole-Wilson PA, Cannon CP. An annual, prospective, international study of outpatients with cardiovascular disease or risk factors: design and methods of the CardioMonitor registry. Crit Pathw Cardiol. 2007 Jun; 6(2):72-5. 294. Adams HP, del Zoppo G, Alberts MJ, Bhatt DL, Brass L, Furlan A, Grubb RL, Higashida RT, Jauch EC, Kidwell C, Lyden PD, Morgenstern LB, Qureshi AI, Rosenwasser RH, Scott PA, Wijdicks EF. Guidelines for the early management of adults with ischemic stroke: a guideline from the American Heart Association/American Stroke Association Stroke Council, Clinical Cardiology Council, Cardiovascular Radiology and Intervention Council, and the Atherosclerotic Peripheral Vascular Disease and Quality of Care Outcomes in Research Interdisciplinary Working Groups: The American Academy of Neurology affirms the value of this guideline as an educational tool for neurologists. Circulation. 2007 May 22; 115(20):e478-534. 295. Cohen M, Bhatt DL, Alexander JH, Montalescot G, Bode C, Henry T, Tamby JF, Saaiman J, Simek S, De Swart J. Randomized, double-blind, dose-ranging study of otamixaban, a novel, parenteral, short-acting direct factor Xa inhibitor, in percutaneous coronary intervention: the SEPIA-PCI trial. Circulation. 2007 May 22; 115(20):2642-51. 296. Meadows TA, Bhatt DL. Clinical aspects of platelet inhibitors and thrombus formation. Circ Res. 2007 May 11; 100(9):1261-75. 297. Bavry AA, Bhatt DL. Acute myocardial infarction and drug-eluting stents: a green light for their use or time for measured restraint? Am Heart J. 2007 May; 153(5):719-21. 298. Steinhubl SR, Badimon JJ, Bhatt DL, Herbert JM, Lüscher TF. Clinical evidence for anti-inflammatory effects of antiplatelet therapy in patients with atherothrombotic disease. Vasc Med. 2007 May; 12(2):113-22. 299. Gurm HS, Rajagopal V, Bhatt DL, Ellis SG, Lincoff AM. The safety of a bivalirudin-based approach in patients undergoing rotational atherectomy. J Invasive Cardiol. 2007 May; 19(5):225-8. 300. Glauser J, Erickson J, Bhatt D, Lindsell C, Gibler B, Hoekstra J, Pollack C, Hollander J, Peacock WF. Elevated serum cardiac markers predict coronary artery disease in patients with a history of heart failure who present with chest pain: insights from the i*trACS registry. Congest Heart Fail. 2007 May-Jun; 13(3):142-8. 301. Adams HP, del Zoppo G, Alberts MJ, Bhatt DL, Brass L, Furlan A, Grubb RL, Higashida RT, Jauch EC, Kidwell C, Lyden PD, Morgenstern LB, Qureshi AI, Rosenwasser RH, Scott PA, Wijdicks EF. Guidelines for the early management of adults with ischemic stroke: a guideline from the American Heart Association/American Stroke Association Stroke Council, Clinical Cardiology Council, Cardiovascular Radiology and Intervention Council, and the Atherosclerotic Peripheral Vascular Disease and Quality of Care Outcomes in Research Interdisciplinary Working Groups: the American Academy of Neurology affirms the value of this guideline as an educational tool for neurologists. Stroke. 2007 May; 38(5):1655-711. 302. Bhatt DL, Flather MD, Hacke W, Berger PB, Black HR, Boden WE, Cacoub P, Cohen EA, Creager MA, Easton JD, Hamm CW, Hankey GJ, Johnston SC, Mak KH, Mas JL, Montalescot G, Pearson TA, Steg PG, Steinhubl SR, Weber MA, Fabry-Ribaudo L, Hu T, Topol EJ, Fox KA. Patients with prior myocardial infarction, stroke, or symptomatic peripheral arterial disease in the CHARISMA trial. J Am Coll Cardiol. 2007 May 15; 49(19):1982-8. 303. Steg PG, Bhatt DL, Wilson PW, D'Agostino R, Ohman EM, Röther J, Liau CS, Hirsch AT, Mas JL, Ikeda Y, Pencina MJ, Goto S. One-year cardiovascular event rates in outpatients with atherothrombosis. JAMA. 2007 Mar 21; 297(11):1197-206. 304. Steinberg BA, Steg PG, Bhatt DL, Fonarow GC, Zeymer U, Cannon CP. Comparisons of guideline-recommended therapies in patients with documented coronary artery disease having percutaneous coronary intervention versus coronary artery bypass grafting versus medical therapy only (from the REACH International Registry). Am J Cardiol. 2007 May 1; 99(9):1212-5. 305. Kumbhani DJ, Bavry AA, Bhatt DL. Late stent thrombosis with drug-eluting stents: the price to pay to prevent restenosis? Indian Heart J. 2007 Mar-Apr; 59(2 Suppl B):B113-7. 306. Abu Romeh IS, Chhatriwalla AK, Atik FA, Bhatt DL, Navia JL. Myocardial infarction secondary to a coronary ostial thrombus in antiphospholipid syndrome. Ann Thorac Surg. 2007 Mar; 83(3):1170-1. 307. Mehta RH, Milford-Beland S, Peterson ED, Bhatt DL, Farkouh ME, Brogan GX, Gibler WB, Ohman EM, Roe MT. Characterizing young patients with diabetes and non-ST-segment elevation acute coronary syndromes. Diabetes Care. 2007 Mar; 30(3):731-3. 308. Shishehbor MH, Lauer MS, Singh IM, Chew DP, Karha J, Brener SJ, Moliterno DJ, Ellis SG, Topol EJ, Bhatt DL. In unstable angina or non-ST-segment acute coronary syndrome, should patients with multivessel coronary artery disease undergo multivessel or culprit-only stenting? J Am Coll Cardiol. 2007 Feb 27; 49(8):849-54. 309. Bavry AA, Chiu JH, Jefferson BK, Karha J, Bhatt DL, Ellis SG, Whitlow PL. Development of coronary aneurysm after drug-eluting stent implantation. Ann Intern Med. 2007 Feb 6; 146(3):230-2. 310. Kelly P, Bhatt DL. Identification of vulnerable plaque--the quest continues. J Invasive Cardiol. 2007 Feb; 19(2):55-7. 311. Rabbat MG, Bavry AA, Bhatt DL, Ellis SG. Understanding and minimizing late thrombosis of drug-eluting stents. Cleve Clin J Med. 2007 Feb; 74(2):129-36. 312. Patel TN, Shishehbor MH, Bhatt DL. A review of high-dose statin therapy: targeting cholesterol and inflammation in atherosclerosis. Eur Heart J. 2007 Mar; 28(6):664-72. 313. Bavry AA, Mood GR, Kumbhani DJ, Borek PP, Askari AT, Bhatt DL. Long-term benefit of statin therapy initiated during hospitalization for an acute coronary syndrome: a systematic review of randomized trials. Am J Cardiovasc Drugs. 2007; 7(2):135-41. 314. John JM, Bhatt DL. Emerging risk factors for atherosclerosis. Indian Heart J. 2007 Jan-Feb; 59(1):28-37. 315. Rabbat MG, Bavry AA, Bhatt DL. Drug-eluting stents: can we move beyond stent thrombosis? Am Heart Hosp J. 2007; 5(3):155-8. 316. Helton TJ, Bavry AA, Kumbhani DJ, Duggal S, Roukoz H, Bhatt DL. Incremental effect of clopidogrel on important outcomes in patients with cardiovascular disease: a meta-analysis of randomized trials. Am J Cardiovasc Drugs. 2007; 7(4):289-97. 317. Bavry AA, Kumbhani DJ, Helton TJ, Borek PP, Mood GR, Bhatt DL. Late thrombosis of drug-eluting stents: a meta-analysis of randomized clinical trials. Am J Med. 2006 Dec; 119(12):1056-61. 318. Chhatriwalla AK, Bhatt DL. Walk this way: early ambulation after cardiac catheterization--good for the patient and the health care system. Mayo Clin Proc. 2006 Dec; 81(12):1535-6. 319. Bhatt DL. Shifting the diagnosis of periprocedural myocardial infarction upstream. Circulation. 2006 Oct 31; 114(18):1898-900. 320. Touzé E, Mas JL, Röther J, Goto S, Hirsch AT, Ikeda Y, Liau CS, Ohman EM, Richard AJ, Wilson PW, Steg PG, Bhatt DL. Impact of carotid endarterectomy on medical secondary prevention after a stroke or a transient ischemic attack: results from the Reduction of Atherothrombosis for Continued Health (REACH) registry. Stroke. 2006 Dec; 37(12):2880-5. 321. Cannon CP, Bhatt DL. Clinical trials update from the annual scientific session of the American College of Cardiology 2006. Am J Cardiol. 2006 Dec 18; 98(12A):36Q-41Q. 322. Bhatt DL. Identification of and management approaches for the high-risk patient. Am J Cardiol. 2006 Dec 18; 98(12A):22Q-29Q. 323. Exaire JE, Fathi RB, Brener SJ, Karha J, Ellis SG, Bhatt DL. Impaired myocardial perfusion score and inflammatory markers in patients undergoing primary angioplasty for acute myocardial infarction. Arch Cardiol Mex. 2006 Oct-Dec; 76(4):376-82. 324. Almahameed A, Bhatt DL. Contemporary management of peripheral arterial disease: III. Endovascular and surgical management. Cleve Clin J Med. 2006 Oct; 73 Suppl 4:S45-51. 325. Patel MR, Chen AY, Peterson ED, Newby LK, Pollack CV, Brindis RG, Gibson CM, Kleiman NS, Saucedo JF, Bhatt DL, Gibler WB, Ohman EM, Harrington RA, Roe MT. Prevalence, predictors, and outcomes of patients with non-ST-segment elevation myocardial infarction and insignificant coronary artery disease: results from the Can Rapid risk stratification of Unstable angina patients Suppress ADverse outcomes with Early implementation of the ACC/AHA Guidelines (CRUSADE) initiative. Am Heart J. 2006 Oct; 152(4):641-7. 326. Saw J, Bhatt DL, Moliterno DJ, Brener SJ, Steinhubl SR, Lincoff AM, Tcheng JE, Harrington RA, Simoons M, Hu T, Sheikh MA, Kereiakes DJ, Topol EJ. The influence of peripheral arterial disease on outcomes: a pooled analysis of mortality in eight large randomized percutaneous coronary intervention trials. J Am Coll Cardiol. 2006 Oct 17; 48(8):1567-72. 327. Bavry AA, Kumbhani DJ, Rassi AN, Bhatt DL, Askari AT. Benefit of early invasive therapy in acute coronary syndromes: a meta-analysis of contemporary randomized clinical trials. J Am Coll Cardiol. 2006 Oct 3; 48(7):1319-25. 328. Bavry AA, Bhatt DL. Bare metal stents: no longer passé? J Invasive Cardiol. 2006 Sep; 18(9):403-4. 329. Tricoci P, Peterson ED, Mulgund J, Newby LK, Saucedo JF, Kleiman NS, Bhatt DL, Berger PB, Cannon CP, Cohen DJ, Hochman JS, Ohman EM, Gibler WB, Harrington RA, Smith SC, Roe MT. Temporal trends in the use of early cardiac catheterization in patients with non-ST-segment elevation acute coronary syndromes (results from CRUSADE). Am J Cardiol. 2006 Nov 1; 98(9):1172-6. 330. Karha J, Gurm HS, Rajagopal V, Fathi R, Bavry AA, Brener SJ, Lincoff AM, Ellis SG, Bhatt DL. Use of platelet glycoprotein IIb/IIIa inhibitors in saphenous vein graft percutaneous coronary intervention and clinical outcomes. Am J Cardiol. 2006 Oct 1; 98(7):906-10. 331. Shishehbor MH, Patel T, Bhatt DL. Using statins to treat inflammation in acute coronary syndromes: Are we there yet? Cleve Clin J Med. 2006 Aug; 73(8):760-6. 332. Serebruany VL, Malinin AI, Bhatt DL. Paradoxical rebound platelet activation after painkillers cessation: missing risk for vascular events? Am J Med. 2006 Aug; 119(8):707.e11-6. 333. Bhatheja R, Bhatt DL. Clinical outcomes in metabolic syndrome. J Cardiovasc Nurs. 2006 Jul-Aug; 21(4):298-305. 334. Bhatt DL. NSAIDS and the risk of myocardial infarction: do they help or harm? Eur Heart J. 2006 Jul; 27(14):1635-6. 335. Rajagopal V, Bhatt DL. Gaps in myocardial infarction care: how might we best EFFECT change? Eur Heart J. 2006 Jul; 27(13):1513-4. 336. Chen MS, John JM, Chew DP, Lee DS, Ellis SG, Bhatt DL. Bare metal stent restenosis is not a benign clinical entity. Am Heart J. 2006 Jun; 151(6):1260-4. 337. Bavry AA, Bhatt DL. Interpreting observational studies -- look before you leap. J Clin Epidemiol. 2006 Aug; 59(8):763-4. 338. Barman N, Bhatt DL. Antithrombotic therapy for percutaneous coronary intervention. Cardiol Clin. 2006 May; 24(2):175-99, v-vi. 339. Karha J, Rajagopal V, Kottke-Marchant K, Bhatt DL. Lack of effect of enteric coating on aspirin-induced inhibition of platelet aggregation in healthy volunteers. Am Heart J. 2006 May; 151(5):976.e7-11. 340. Tricoci P, Roe MT, Mulgund J, Newby LK, Smith SC, Pollack CV, Fintel DJ, Cannon CP, Bhatt DL, Gibler WB, Ohman EM, Peterson ED, Harrington RA. Clopidogrel to treat patients with non-ST-segment elevation acute coronary syndromes after hospital discharge. Arch Intern Med. 2006 Apr 10; 166(7):806-11. 341. Ellis SG, Bhatt D, Kapadia S, Lee D, Yen M, Whitlow PL. Correlates and outcomes of retroperitoneal hemorrhage complicating percutaneous coronary intervention. Catheter Cardiovasc Interv. 2006 Apr; 67(4):541-5. 342. Ohman EM, Bhatt DL, Steg PG, Goto S, Hirsch AT, Liau CS, Mas JL, Richard AJ, Röther J, Wilson PW. The REduction of Atherothrombosis for Continued Health (REACH) Registry: an international, prospective, observational investigation in subjects at risk for atherothrombotic events-study design. Am Heart J. 2006 Apr; 151(4):786.e1-10. 343. Bhatt DL. Can clopidogrel and aspirin lower mortality in patients with acute myocardial infarction? Nat Clin Pract Cardiovasc Med. 2006 Apr; 3(4):182-3. 344. Bhatt DL, Fox KA, Hacke W, Berger PB, Black HR, Boden WE, Cacoub P, Cohen EA, Creager MA, Easton JD, Flather MD, Haffner SM, Hamm CW, Hankey GJ, Johnston SC, Mak KH, Mas JL, Montalescot G, Pearson TA, Steg PG, Steinhubl SR, Weber MA, Brennan DM, Fabry-Ribaudo L, Booth J, Topol EJ. Clopidogrel and aspirin versus aspirin alone for the prevention of atherothrombotic events. N Engl J Med. 2006 Apr 20; 354(16):1706-17. 345. Chhatriwalla AK, Bhatt DL. You can't keep a good man (or woman) down. J Invasive Cardiol. 2006 Mar; 18(3):109-10. 346. Duffy BK, Gurm HS, Rajagopal V, Gupta R, Ellis SG, Bhatt DL. Usefulness of an elevated neutrophil to lymphocyte ratio in predicting long-term mortality after percutaneous coronary intervention. Am J Cardiol. 2006 Apr 1; 97(7):993-6. 347. Bhatt DL, Steg PG, Ohman EM, Hirsch AT, Ikeda Y, Mas JL, Goto S, Liau CS, Richard AJ, Röther J, Wilson PW. International prevalence, recognition, and treatment of cardiovascular risk factors in outpatients with atherothrombosis. JAMA. 2006 Jan 11; 295(2):180-9. 348. Brogan GX, Peterson ED, Mulgund J, Bhatt DL, Ohman EM, Gibler WB, Pollack CV, Farkouh ME, Roe MT. Treatment disparities in the care of patients with and without diabetes presenting with non-ST-segment elevation acute coronary syndromes. Diabetes Care. 2006 Jan; 29(1):9-14. 349. Bhatt DL. Clopidogrel bisulfate in st-segment elevation myocardial infarction: a viewpoint by Deepak L Bhatt. Am J Cardiovasc Drugs. 2006; 6(6):415. 350. Serebruany VL, Pokov AN, Malinin AI, O'Connor C, Bhatt DL, Tanguay JF, Sane DC, Hennekens CH. Valsartan inhibits platelet activity at different doses in mild to moderate hypertensives: Valsartan Inhibits Platelets (VIP) trial. Am Heart J. 2006 Jan; 151(1):92-9. 351. Chew DP, Bhatt DL, Lincoff AM, Wolski K, Topol EJ. Clinical end point definitions after percutaneous coronary intervention and their relationship to late mortality: an assessment by attributable risk. Heart. 2006 Jul; 92(7):945-50. 352. Wang TH, Bhatt DL, Topol EJ. Aspirin and clopidogrel resistance: an emerging clinical entity. Eur Heart J. 2006 Mar; 27(6):647-54. 353. Fathi RB, Gurm HS, Chew DP, Gupta R, Bhatt DL, Ellis SG. The interaction of vascular inflammation and chronic kidney disease for the prediction of long-term death after percutaneous coronary intervention. Am Heart J. 2005 Dec; 150(6):1190-7. 354. Bhatt D, Tu C, Fisher SZ, Hernandez Prada JA, McKenna R, Silverman DN. Proton transfer in a Thr200His mutant of human carbonic anhydrase II. Proteins. 2005 Nov 1; 61(2):239-45. 355. Ghaffari G, Tuttle DL, Briggs D, Burkhardt BR, Bhatt D, Andiman WA, Sleasman JW, Goodenow MM. Complex determinants in human immunodeficiency virus type 1 envelope gp120 mediate CXCR4-dependent infection of macrophages. J Virol. 2005 Nov; 79(21):13250-61. 356. Selvaraj CL, Gurm HS, Gupta R, Ellis SG, Bhatt DL. Chronic obstructive pulmonary disease as a predictor of mortality in patients undergoing percutaneous coronary intervention. Am J Cardiol. 2005 Sep 15; 96(6):756-9. 357. Serebruany VL, Malinin AI, Ziai W, Pokov AN, Bhatt DL, Alberts MJ, Hanley DF. Effects of clopidogrel and aspirin in combination versus aspirin alone on platelet activation and major receptor expression in patients after recent ischemic stroke: for the Plavix Use for Treatment of Stroke (PLUTO-Stroke) trial. Stroke. 2005 Oct; 36(10):2289-92. 358. Bhatt DL, Fox KA, Hacke W, Berger PB, Black HR, Boden WE, Cacoub P, Cohen EA, Creager MA, Easton JD, Flather MD, Haffner SM, Hamm CW, Hankey GJ, Johnston SC, Mak KH, Mas JL, Montalescot G, Pearson TA, Steg PG, Steinhubl SR, Weber MA, Booth J, Topol EJ. A global view of atherothrombosis: baseline characteristics in the Clopidogrel for High Atherothrombotic Risk and Ischemic Stabilization, Management, and Avoidance (CHARISMA) trial. Am Heart J. 2005 Sep; 150(3):401. 359. Chen MS, Bhatt DL, Chew DP, Moliterno DJ, Ellis SG, Topol EJ. Outcomes in African Americans and whites after percutaneous coronary intervention. Am J Med. 2005 Sep; 118(9):1019-25. 360. Ziada KM, Yadav JS, Mukherjee D, Lauer MS, Bhatt DL, Kapadia S, Roffi M, Vora N, Tiong I, Bajzer C. Comparison of results of carotid stenting followed by open heart surgery versus combined carotid endarterectomy and open heart surgery (coronary bypass with or without another procedure). Am J Cardiol. 2005 Aug 15; 96(4):519-23. 361. Aronow HD, Shishehbor M, Davis DA, Katzan IL, Bhatt DL, Bajzer CT, Abou-Chebl A, Derk KW, Whitlow PL, Yadav JS. Leukocyte count predicts microembolic Doppler signals during carotid stenting: a link between inflammation and embolization. Stroke. 2005 Sep; 36(9):1910-4. 362. Bhatt DL, Topol EJ. Does creatinine kinase-MB elevation after percutaneous coronary intervention predict outcomes in 2005? Periprocedural cardiac enzyme elevation predicts adverse outcomes. Circulation. 2005 Aug 9; 112(6):906-15; discussion 923. 363. Bhatt DL. To cath or not to cath: that is no longer the question. JAMA. 2005 Jun 15; 293(23):2935-7. 364. Bavry AA, Kumbhani DJ, Helton TJ, Bhatt DL. Risk of thrombosis with the use of sirolimus-eluting stents for percutaneous coronary intervention (from registry and clinical trial data). Am J Cardiol. 2005 Jun 15; 95(12):1469-72. 365. Rajagopal V, Bhatt DL. Acute coronary syndrome statistics: what you don't see can hurt you. Am Heart J. 2005 Jun; 149(6):955-6. 366. Fathi RB, Bhatt DL. Enhancing reperfusion therapy for myocardial infarction with dual antiplatelet therapy: Breaking the glass ceiling. Am Heart J. 2005 Jun; 149(6):947-9. 367. Serebruany VL, Steinhubl SR, Berger PB, Malinin AI, Baggish JS, Bhatt DL, Topol EJ. Analysis of risk of bleeding complications after different doses of aspirin in 192,036 patients enrolled in 31 randomized controlled trials. Am J Cardiol. 2005 May 15; 95(10):1218-22. 368. Bhatt DL, Aranki S, Byrne J, Bhatia D, Mehta S, Mills R. Issues in the management of antiplatelet therapy in patients undergoing surgical revascularization. A roundtable discussion. J Invasive Cardiol. 2005 May; 17(5):283-7. 369. Gupta R, Gurm HS, Bhatt DL, Chew DP, Ellis SG. Renal failure after percutaneous coronary intervention is associated with high mortality. Catheter Cardiovasc Interv. 2005 Apr; 64(4):442-8. 370. Chan AW, Yadav JS, Bhatt DL, Bajzer CT, Gum PA, Roffi M, Cho L, Agah R, Topol EJ. Comparison of the safety and efficacy of emboli prevention devices versus platelet glycoprotein IIb/IIIa inhibition during carotid stenting. Am J Cardiol. 2005 Mar 15; 95(6):791-5. 371. Bavry AA, Kumbhani DJ, Helton TJ, Bhatt DL. What is the risk of stent thrombosis associated with the use of paclitaxel-eluting stents for percutaneous coronary intervention?: a meta-analysis. J Am Coll Cardiol. 2005 Mar 15; 45(6):941-6. 372. Gurm HS, Rajagopal V, Fathi R, Vivekanathan D, Yadav JS, Bhatt DL, Ellis SG, Lincoff AM, Topol EJ. Effectiveness and safety of bivalirudin during percutaneous coronary intervention in a single medical center. Am J Cardiol. 2005 Mar 15; 95(6):716-21. 373. Rajagopal V, Bhatt DL. Factor Xa inhibitors in acute coronary syndromes: moving from mythology to reality. J Thromb Haemost. 2005 Mar; 3(3):436-8. 374. Rajagopal V, Gurm HS, Brunken RC, Pothier CE, Bhatt DL, Lauer MS. Prediction of death or myocardial infarction by exercise single photon emission computed tomography perfusion scintigraphy in patients who have had recent coronary artery stenting. Am Heart J. 2005 Mar; 149(3):534-40. 375. Karha J, Bhatt DL. Plaque regression--a new target for antiatherosclerotic therapy. Am Heart J. 2005 Mar; 149(3):384-7. 376. Serebruany VL, Steinhubl SR, Berger PB, Malinin AI, Bhatt DL, Topol EJ. Variability in platelet responsiveness to clopidogrel among 544 individuals. J Am Coll Cardiol. 2005 Jan 18; 45(2):246-51. 377. Yen MH, Lee DS, Kapadia S, Sachar R, Bhatt DL, Bajzer CT, Yadav JS. Symptomatic patients have similar outcomes compared with asymptomatic patients after carotid artery stenting with emboli protection. Am J Cardiol. 2005 Jan 15; 95(2):297-300. 378. Duffy B, Bhatt DL. Antiplatelet agents in patients undergoing percutaneous coronary intervention: how many and how much? Am J Cardiovasc Drugs. 2005; 5(5):307-18. 379. Gurm HS, Bhatt DL. Thrombin, an ideal target for pharmacological inhibition: a review of direct thrombin inhibitors. Am Heart J. 2005 Jan; 149(1 Suppl):S43-53. 380. Saw J, Bhatt DL. The evolving role of percutaneous intervention in coronary artery disease with coexistent aortic stenosis. J Invasive Cardiol. 2004 Dec; 16(12):692-3. 381. Exaire JE, Brener SJ, Ellis SG, Yadav JS, Bhatt DL. GuardWire emboli protection device is associated with improved myocardial perfusion grade in saphenous vein graft intervention. Am Heart J. 2004 Dec; 148(6):1003-6. 382. Geisler T, Bhatt DL. The role of inflammation in atherothrombosis: current and future strategies of medical treatment. Med Sci Monit. 2004 Dec; 10(12):RA308-16. 383. Chiu JH, Bhatt DL, Ziada KM, Chew DP, Whitlow PL, Lincoff AM, Ellis SG, Topol EJ. Impact of female sex on outcome after percutaneous coronary intervention. Am Heart J. 2004 Dec; 148(6):998-1002. 384. Rajagopal V, Bhatt DL. Controversies of oral antiplatelet therapy in acute coronary syndromes and percutaneous coronary intervention. Semin Thromb Hemost. 2004 Dec; 30(6):649-55. 385. Bhatt DL, Roe MT, Peterson ED, Li Y, Chen AY, Harrington RA, Greenbaum AB, Berger PB, Cannon CP, Cohen DJ, Gibson CM, Saucedo JF, Kleiman NS, Hochman JS, Boden WE, Brindis RG, Peacock WF, Smith SC, Pollack CV, Gibler WB, Ohman EM. Utilization of early invasive management strategies for high-risk patients with non-ST-segment elevation acute coronary syndromes: results from the CRUSADE Quality Improvement Initiative. JAMA. 2004 Nov 3; 292(17):2096-104. 386. Hirsh J, Bhatt DL. Comparative benefits of clopidogrel and aspirin in high-risk patient populations: lessons from the CAPRIE and CURE studies. Arch Intern Med. 2004 Oct 25; 164(19):2106-10. 387. Saw J, Gurm HS, Fathi RB, Bhatt DL, Abou-Chebl A, Bajzer C, Yadav JS. Effect of chronic kidney disease on outcomes after carotid artery stenting. Am J Cardiol. 2004 Oct 15; 94(8):1093-6. 388. Ellis SG, Bajzer CT, Bhatt DL, Brener SJ, Whitlow PL, Lincoff AM, Moliterno DJ, Raymond RE, Tuzcu EM, Franco I, Dushman-Ellis S, Lander KJ, Schneider JP, Topol EJ. Real-world bare metal stenting: identification of patients at low or very low risk of 9-month coronary revascularization. Catheter Cardiovasc Interv. 2004 Oct; 63(2):135-40. 389. Komadja M, Levy S, Steg PG, Bhatt DL. [New concepts in cardiology]. Presse Med. 2004 Sep 25; 33(16):1132-4. 390. Bhatt DL. Peripheral arterial disease in the catheterization laboratory: an underdetected and undertreated risk factor. Mayo Clin Proc. 2004 Sep; 79(9):1107-9. 391. Chacko M, Marrouche NF, Bhatt DL. Asymptomatic acute inferior ST elevation myocardial infarction from thermal injury complicating radiofrequency ablation for atrioventricular re-entrant tachycardia. J Invasive Cardiol. 2004 Sep; 16(9):504-5. 392. John JM, Bhatt DL. Management of acute coronary syndrome in diabetes mellitus. Herz. 2004 Aug; 29(5):532-41. 393. Bhatt DL, Topol EJ. Clopidogrel added to aspirin versus aspirin alone in secondary prevention and high-risk primary prevention: rationale and design of the Clopidogrel for High Atherothrombotic Risk and Ischemic Stabilization, Management, and Avoidance (CHARISMA) trial. Am Heart J. 2004 Aug; 148(2):263-8. 394. Karha J, Bhatt DL. Percutaneous coronary intervention in diabetics. Rev Endocr Metab Disord. 2004 Aug; 5(3):277-85. 395. Vivekananthan DP, Bhatt DL, Chew DP, Zidar FJ, Chan AW, Moliterno DJ, Ellis SG, Topol EJ. Effect of clopidogrel pretreatment on periprocedural rise in C-reactive protein after percutaneous coronary intervention. Am J Cardiol. 2004 Aug 1; 94(3):358-60. 396. Rajagopal V, Gurm HS, Bhatt DL, Lincoff AM, Tcheng JE, Kereiakes DJ, Kleiman NS, Jia G, Topol EJ. Relation of an elevated white blood cell count after percutaneous coronary intervention to long-term mortality. Am J Cardiol. 2004 Jul 15; 94(2):190-2. 397. Mills R, Bhatt DL. The Yin and Yang of arterial inflammation. J Am Coll Cardiol. 2004 Jul 7; 44(1):50-2. 398. Bhatt DL. Bleeding complications during percutaneous coronary intervention. J Invasive Cardiol. 2004 Jul; 16(7 Suppl):24S-29S. 399. Topol EJ, Bhatt DL, Penn M, Tuzcu EM, Herrmann H. The future--panel discussion. J Invasive Cardiol. 2004 Jul; 16(7 Suppl):65S-66S. 400. Topol EJ, Bhatt DL, Simonton C, Steinhubl S, Lincoff AM. Here and now--state of the art: optimal antithrombotic strategy for percutaneous coronary intervention-panel discussion. J Invasive Cardiol. 2004 Jul; 16(7 Suppl):30S-31S. 401. Bhatt DL. Emboli protection devices. J Invasive Cardiol. 2004 Jul; 16(7 Suppl):45S-49S. 402. Bhatt DL. Inflammation and restenosis: is there a link? Am Heart J. 2004 Jun; 147(6):945-7. 403. Abou-Chebl A, Yadav JS, Reginelli JP, Bajzer C, Bhatt D, Krieger DW. Intracranial hemorrhage and hyperperfusion syndrome following carotid artery stenting: risk factors, prevention, and treatment. J Am Coll Cardiol. 2004 May 5; 43(9):1596-601. 404. Sachar R, Yadav JS, Roffi M, Cho L, Reginelli JP, Aböu-Chebl A, Bhatt DL, Bajzer CT. Severe bilateral carotid stenosis: the impact of ipsilateral stenting on Doppler-defined contralateral stenosis. J Am Coll Cardiol. 2004 Apr 21; 43(8):1358-62. 405. Bhatt DL. Embolization--a pathological mechanism in renal artery stenosis. J Invasive Cardiol. 2004 Apr; 16(4):196-7. 406. Chen MS, Bhatt DL, Mukherjee D, Chan AW, Roffi M, Kapadia SR, Ziada KM, Chew DP, Bajzer CT, Yadav JS. Feasibility of simultaneous bilateral carotid artery stenting. Catheter Cardiovasc Interv. 2004 Apr; 61(4):437-42. 407. Quinn MJ, Aronow HD, Califf RM, Bhatt DL, Sapp S, Kleiman NS, Harrington RA, Kong DF, Kandzari DE, Topol EJ. Aspirin dose and six-month outcome after an acute coronary syndrome. J Am Coll Cardiol. 2004 Mar 17; 43(6):972-8. 408. Bhatt DL. Aspirin resistance: more than just a laboratory curiosity. J Am Coll Cardiol. 2004 Mar 17; 43(6):1127-9. 409. Quinn MJ, Bhatt DL, Zidar F, Vivekananthan D, Chew DP, Ellis SG, Plow E, Topol EJ. Effect of clopidogrel pretreatment on inflammatory marker expression in patients undergoing percutaneous coronary intervention. Am J Cardiol. 2004 Mar 15; 93(6):679-84. 410. Shishehbor MH, Bhatt DL. Inflammation and atherosclerosis. Curr Atheroscler Rep. 2004 Mar; 6(2):131-9. 411. Haery C, Exaire JE, Bhatt DL, Yadav JS, Franco I, Ellis SG. Use of PercuSurge GuardWire in native coronary arteries during acute myocardial infarction. J Invasive Cardiol. 2004 Mar; 16(3):152-4. 412. Tamberella MR, Yadav JS, Bajzer CT, Bhatt DL, Abou-Chebl A. Cutting balloon angioplasty to treat carotid in-stent restenosis. J Invasive Cardiol. 2004 Mar; 16(3):133-5. 413. Merritt JC, Bhatt DL. The efficacy and safety of perioperative antiplatelet therapy. J Thromb Thrombolysis. 2004 Feb; 17(1):21-7. 414. Lee DS, Bhatt DL, Moliterno DJ, Peacock WF, Ellis SG, Topol EJ. The combination of enoxaparin, glycoprotein IIb/IIIa inhibitors and an early invasive approach among acute coronary syndrome patients. J Invasive Cardiol. 2004 Feb; 16(2):46-51. 415. Ringleb PA, Bhatt DL, Hirsch AT, Topol EJ, Hacke W. Benefit of clopidogrel over aspirin is amplified in patients with a history of ischemic events. Stroke. 2004 Feb; 35(2):528-32. 416. Maksimowicz-McKinnon K, Bhatt DL, Calabrese LH. Recent advances in vascular inflammation: C-reactive protein and other inflammatory biomarkers. Curr Opin Rheumatol. 2004 Jan; 16(1):18-24. 417. Cho L, Roffi M, Mukherjee D, Bhatt DL, Bajzer C, Yadav JS. Superficial femoral artery occlusion: nitinol stents achieve flow and reduce the need for medications better than balloon angioplasty alone. J Invasive Cardiol. 2004 Jan; 16 Suppl A:20A-22A. 418. Brener SJ, Bhatt DL, Moliterno DJ, Schneider JP, Ellis SG, Topol EJ. Revisiting optimal anticoagulation with unfractionated heparin during coronary stent implantation. Am J Cardiol. 2003 Dec 15; 92(12):1468-71. 419. Jneid H, Bhatt DL. Advances in antiplatelet therapy. Expert Opin Emerg Drugs. 2003 Nov; 8(2):349-63. 420. Chew DP, Bhatt DL, Kimball W, Henry TD, Berger P, McCullough PA, Feit F, Bittl JA, Lincoff AM. Bivalirudin provides increasing benefit with decreasing renal function: a meta-analysis of randomized trials. Am J Cardiol. 2003 Oct 15; 92(8):919-23. 421. Hostetter JC, Bhatt DL. The expanding role of antiplatelet agents in coronary artery disease. A current review of aspirin, glycoprotein IIb/IIIa inhibitors, and the thienopyridines. Minerva Cardioangiol. 2003 Oct; 51(5):531-46. 422. Gurm HS, Bhatt DL, Lincoff AM, Tcheng JE, Kereiakes DJ, Kleiman NS, Jia G, Topol EJ. Impact of preprocedural white blood cell count on long term mortality after percutaneous coronary intervention: insights from the EPIC, EPILOG, and EPISTENT trials. Heart. 2003 Oct; 89(10):1200-4. 423. Gurm HS, Bhatt DL, Gupta R, Ellis SG, Topol EJ, Lauer MS. Preprocedural white blood cell count and death after percutaneous coronary intervention. Am Heart J. 2003 Oct; 146(4):692-8. 424. Chan AW, Moliterno DJ, Berger PB, Stone GW, DiBattiste PM, Yakubov SL, Sapp SK, Wolski K, Bhatt DL, Topol EJ. Triple antiplatelet therapy during percutaneous coronary intervention is associated with improved outcomes including one-year survival: results from the Do Tirofiban and ReoProGive Similar Efficacy Outcome Trial (TARGET). J Am Coll Cardiol. 2003 Oct 1; 42(7):1188-95. 425. Kereiakes DJ, Tcheng J, Fry ET, Bhatt DL, Bosker G, Diez JG, Ferguson JJ, Levine GN, Schaer GL, Zidar J. Pharmacoinvasive management of acute coronary syndrome in the setting of percutaneous coronary intervention: evidence-based, site- and spectrum-of-care strategies for optimizing patient outcomes in NSTE-ACS. J Invasive Cardiol. 2003 Sep; 15(9):536-53. 426. Yen MH, Bhatt DL, Chew DP, Harrington RA, Newby LK, Ardissino D, Van de Werf F, White JA, Moliterno DJ, Topol EJ. Association between admission white blood cell count and one-year mortality in patients with acute coronary syndromes. Am J Med. 2003 Sep; 115(4):318-21. 427. L'Allier PL, Aronow HD, Cura FA, Bhatt DL, Albirini A, Schneider JP, Topol EJ, Ellis SG. Clopidogrel is associated with better in-hospital and 30-day outcomes than ticlopidine after coronary stenting. Can J Cardiol. 2003 Aug; 19(9):1041-6. 428. Bhatt DL, Chew DP, Lincoff AM, Simoons ML, Harrington RA, Ommen SR, Jia G, Topol EJ. Effect of revascularization on mortality associated with an elevated white blood cell count in acute coronary syndromes. Am J Cardiol. 2003 Jul 15; 92(2):136-40. 429. Shishehbor MH, Bhatt DL, Topol EJ. Using C-reactive protein to assess cardiovascular disease risk. Cleve Clin J Med. 2003 Jul; 70(7):634-40. 430. Jneid H, Bhatt DL, Corti R, Badimon JJ, Fuster V, Francis GS. Aspirin and clopidogrel in acute coronary syndromes: therapeutic insights from the CURE study. Arch Intern Med. 2003 May 26; 163(10):1145-53. 431. Bhatt DL. Heparin in peripheral vascular intervention--time for a change? J Invasive Cardiol. 2003 May; 15(5):249-50. 432. Chen MS, Bhatt DL. Highlights of the 2002 update to the 2000 American College of Cardiology/American Heart Association acute coronary syndrome guidelines. Cardiol Rev. 2003 May-Jun; 11(3):113-21. 433. Gerschutz GP, Bhatt DL. The Clopidogrel in Unstable Angina to Prevent Recurrent Events (CURE) study: to what extent should the results be generalizable? Am Heart J. 2003 Apr; 145(4):595-601. 434. Cho L, Roffi M, Mukherjee D, Bhatt DL, Bajzer C, Yadav JS. Superficial femoral artery occlusion: nitinol stents achieve better flow and reduce the need for medications than balloon angioplasty alone. J Invasive Cardiol. 2003 Apr; 15(4):198-200. 435. Chan AW, Bhatt DL, Chew DP, Reginelli J, Schneider JP, Topol EJ, Ellis SG. Relation of inflammation and benefit of statins after percutaneous coronary interventions. Circulation. 2003 Apr 8; 107(13):1750-6. 436. Cho L, Chew DP, Moliterno DJ, Roffi M, Ellis SG, Franco I, Bajzer C, Bhatt DL, Dorosti K, Simpfendorder C, Tuzcu M, Yadav JS, Brener S, Raymond R, Whitlow P, Topol EJ, Lincoff AM. Safe and efficacious use of bivalirudin for percutaneous coronary intervention with adjunctive platelet glycoprotein IIb/IIIa receptor inhibition. Am J Cardiol. 2003 Mar 15; 91(6):742-3. 437. Cho L, Bhatt DL, Brennan D, Wilcox RG, Topol EJ. Relation of insurance status to performance of coronary angiography in patients with unstable angina pectoris or acute myocardial infarction. Am J Cardiol. 2003 Mar 15; 91(6):721-3. 438. Bhatt DL. Diffuse coronary disease and atherothrombosis: a rationale for long-term therapy to prevent recurrent ischemic events. J Invasive Cardiol. 2003 Mar; 15 Suppl B:3B-9B; discussion 9B-10B. 439. Popma J, Bhatt DL. Case presentations and discussions. J Invasive Cardiol. 2003 Mar; 15 Suppl B:34B-41B. 440. Cho L, Bhatt DL, Marso SP, Brennan D, Holmes DR, Califf RM, Topol EJ. An invasive strategy is associated with decreased mortality in patients with unstable angina and non-ST-elevation myocardial infarction: GUSTO IIb trial. Am J Med. 2003 Feb 1; 114(2):106-11. 441. Francis GS, Bhatt DL. Ask the doctors. I live in a city with high air pollution. Is this a risk factor for heart disease? Heart Advis. 2003 Feb; 6(2):8. 442. Bhatt DL, Topol EJ. Scientific and therapeutic advances in antiplatelet therapy. Nat Rev Drug Discov. 2003 Jan; 2(1):15-28. 443. Chan AW, Begelman SM, Bhatt DL. Percutaneous thrombin injection for pseudoaneurysm repair. Vasc Med. 2003; 8(3):217-8. 444. Bhatt DL, Lee BI, Casterella PJ, Pulsipher M, Rogers M, Cohen M, Corrigan VE, Ryan TJ, Breall JA, Moses JW, Eaton GM, Sklar MA, Lincoff AM. Safety of concomitant therapy with eptifibatide and enoxaparin in patients undergoing percutaneous coronary intervention: results of the Coronary Revascularization Using Integrilin and Single bolus Enoxaparin Study. J Am Coll Cardiol. 2003 Jan 1; 41(1):20-5. 445. Chan AW, Roffi M, Mukherjee D, Bajzer CT, Abou-Chebl A, Ciezki J, Bhatt DL, Ghaffari S, Yadav JS. Carotid brachytherapy for in-stent restenosis. Catheter Cardiovasc Interv. 2003 Jan; 58(1):86-92. 446. Roffi M, Mukherjee D, Chew DP, Bhatt DL, Cho L, Robbins MA, Ziada KM, Brennan DM, Ellis SG, Topol EJ. Lack of benefit from intravenous platelet glycoprotein IIb/IIIa receptor inhibition as adjunctive treatment for percutaneous interventions of aortocoronary bypass grafts: a pooled analysis of five randomized clinical trials. Circulation. 2002 Dec 10; 106(24):3063-7. 447. Reginelli JP, Bhatt DL. Why diabetics are at risk in percutaneous coronary intervention and the appropriate management of diabetics in interventional cardiology. J Invasive Cardiol. 2002 Dec; 14 Suppl E:2E-10E; quiz 11E. 448. Chan AW, Bhatt DL, Wilkoff BL, Roffi M, Mukherjee D, Gray BH, Baizer CT, Yadav JS. Percutaneous treatment for pacemaker-associated superior vena cava syndrome. Pacing Clin Electrophysiol. 2002 Nov; 25(11):1628-33. 449. Bhatt DL, Topol EJ. The arterial inflammation hypothesis. Arch Intern Med. 2002 Oct 28; 162(19):2249-50; author reply 2250-1. 450. Bhatt DL, Marso SP, Hirsch AT, Ringleb PA, Hacke W, Topol EJ. Amplified benefit of clopidogrel versus aspirin in patients with diabetes mellitus. Am J Cardiol. 2002 Sep 15; 90(6):625-8. 451. Roffi M, Chew DP, Mukherjee D, Bhatt DL, White JA, Moliterno DJ, Heeschen C, Hamm CW, Robbins MA, Kleiman NS, Théroux P, White HD, Topol EJ. Platelet glycoprotein IIb/IIIa inhibition in acute coronary syndromes. Gradient of benefit related to the revascularization strategy. Eur Heart J. 2002 Sep; 23(18):1441-8. 452. Chan AW, Quinn MJ, Bhatt DL, Chew DP, Moliterno DJ, Topol EJ, Ellis SG. Mortality benefit of beta-blockade after successful elective percutaneous coronary intervention. J Am Coll Cardiol. 2002 Aug 21; 40(4):669-75. 453. Bhatt DL, Topol EJ. Need to test the arterial inflammation hypothesis. Circulation. 2002 Jul 2; 106(1):136-40. 454. Chew DP, Bhatt DL. Optimizing glycoprotein IIb/IIIa inhibition: lessons from recent randomized controlled trials. Intern Med J. 2002 Jul; 32(7):338-45. 455. Tamberella MR, Bhatt DL, Chew DP, Kereiakes DJ, Topol EJ, Steinhubl SR. Relation of platelet inactivation with intravenous glycoprotein IIb/IIIa antagonists to major bleeding (from the GOLD study). Am J Cardiol. 2002 Jun 15; 89(12):1429-31. 456. Aviles RJ, Bhatt DL. Antiplatelet therapies in combination for the treatment of patients with stable and unstable coronary artery disease. J Thromb Thrombolysis. 2002 Jun; 13(3):177-82. 457. Jeremias A, Bhatt DL, Chew DP, Ziada KM, Albirini A, Brener SJ, Lincoff AM, Topol EJ, Ellis SG. Safety of abciximab during percutaneous coronary intervention in patients with chronic renal insufficiency. Am J Cardiol. 2002 May 15; 89(10):1209-11. 458. Gerschutz GP, Bhatt DL. The CURE trial: using clopidogrel in acute coronary syndromes without ST-segment elevation. Cleve Clin J Med. 2002 May; 69(5):377-8, 380, 382 passim. 459. Merritt JC, Bhatt DL. The efficacy and safety of perioperative antiplatelet therapy. J Thromb Thrombolysis. 2002 Apr; 13(2):97-103. 460. Bhatt DL, Raymond RE, Feldman T, Braden GA, Murphy B, Strumpf R, Rogers EW, Myla S, Knopf WD. Successful "pre-closure" of 7Fr and 8Fr femoral arteriotomies with a 6Fr suture-based device (the Multicenter Interventional Closer Registry). Am J Cardiol. 2002 Mar 15; 89(6):777-9. 461. Chan AW, Bhatt DL, Chew DP, Quinn MJ, Moliterno DJ, Topol EJ, Ellis SG. Early and sustained survival benefit associated with statin therapy at the time of percutaneous coronary intervention. Circulation. 2002 Feb 12; 105(6):691-6. 462. Chan AW, Chew DP, Bhatt DL, Moliterno DJ, Topol EJ, Ellis SG. Long-term mortality benefit with the combination of stents and abciximab for cardiogenic shock complicating acute myocardial infarction. Am J Cardiol. 2002 Jan 15; 89(2):132-6. 463. Bhatt DL, Bertrand ME, Berger PB, L'Allier PL, Moussa I, Moses JW, Dangas G, Taniuchi M, Lasala JM, Holmes DR, Ellis SG, Topol EJ. Meta-analysis of randomized and registry comparisons of ticlopidine with clopidogrel after stenting. J Am Coll Cardiol. 2002 Jan 2; 39(1):9-14. 464. Lauer MA, Houghtaling PL, Peterson JG, Granger CB, Bhatt DL, Sapp SK, Simoons ML, Harrington RA, Topol EJ, Lincoff AM. Attenuation of rebound ischemia after discontinuation of heparin therapy by glycoprotein IIb/IIIa inhibition with eptifibatide in patients with acute coronary syndromes: observations from the platelet IIb/IIIa in unstable angina: receptor suppression using integrilin therapy (PURSUIT) trial. Circulation. 2001 Dec 4; 104(23):2772-7. 465. Roffi M, Chew DP, Mukherjee D, Bhatt DL, White JA, Heeschen C, Hamm CW, Moliterno DJ, Califf RM, White HD, Kleiman NS, Théroux P, Topol EJ. Platelet glycoprotein IIb/IIIa inhibitors reduce mortality in diabetic patients with non-ST-segment-elevation acute coronary syndromes. Circulation. 2001 Dec 4; 104(23):2767-71. 466. Bhatt DL, Kapadia SR, Bajzer CT, Chew DP, Ziada KM, Mukherjee D, Roffi M, Topol EJ, Yadav JS. Dual antiplatelet therapy with clopidogrel and aspirin after carotid artery stenting. J Invasive Cardiol. 2001 Dec; 13(12):767-71. 467. Mukherjee D, Bhatt DL, Robbins M, Roffi M, Cho L, Reginelli J, Bajzer C, Navarro F, Yadav JS. Renal artery end-diastolic velocity and renal artery resistance index as predictors of outcome after renal stenting. Am J Cardiol. 2001 Nov 1; 88(9):1064-6. 468. Mukherjee D, Kalahasti V, Roffi M, Bhatt DL, Kapadia SR, Bajzer C, Reginelli J, Ziada KM, Hughes K, Yadav JS. Self-expanding stents for carotid interventions: comparison of nitinol versus stainless-steel stents. J Invasive Cardiol. 2001 Nov; 13(11):732-5. 469. Kapadia SR, Bajzer CT, Ziada KM, Bhatt DL, Wazni OM, Silver MJ, Beven EG, Ouriel K, Yadav JS. Initial experience of platelet glycoprotein IIb/IIIa inhibition with abciximab during carotid stenting: a safe and effective adjunctive therapy. Stroke. 2001 Oct; 32(10):2328-32. 470. Chew DP, Bhatt DL, Robbins MA, Mukherjee D, Roffi M, Schneider JP, Topol EJ, Ellis SG. Effect of clopidogrel added to aspirin before percutaneous coronary intervention on the risk associated with C-reactive protein. Am J Cardiol. 2001 Sep 15; 88(6):672-4. 471. Chew DP, Bhatt DL, Robbins MA, Penn MS, Schneider JP, Lauer MS, Topol EJ, Ellis SG. Incremental prognostic value of elevated baseline C-reactive protein among established markers of risk in percutaneous coronary intervention. Circulation. 2001 Aug 28; 104(9):992-7. 472. Mukherjee D, Comella K, Bhatt DL, Roe MT, Patel V, Ellis SG. Clinical outcome of a cohort of patients eligible for therapeutic angiogenesis or transmyocardial revascularization. Am Heart J. 2001 Jul; 142(1):72-4. 473. Mukherjee D, Roffi M, Kapadia SR, Bhatt DL, Bajzer C, Ziada KM, Kalahasti V, Hughes K, Yadav JS. Percutaneous intervention for symptomatic vertebral artery stenosis using coronary stents. J Invasive Cardiol. 2001 May; 13(5):363-6. 474. Cho L, Bhatt DL, Wolski K, Lincoff M, Topol EJ, Moliterno DJ. Effect of smoking status and abciximab use on outcome after percutaneous coronary revascularization: Pooled analysis from EPIC, EPILOG, and EPISTENT. Am Heart J. 2001 Apr; 141(4):599-602. 475. Chew DP, Bhatt DL, Lincoff AM, Moliterno DJ, Brener SJ, Wolski KE, Topol EJ. Defining the optimal activated clotting time during percutaneous coronary intervention: aggregate results from 6 randomized, controlled trials. Circulation. 2001 Feb 20; 103(7):961-6. 476. Bhatt DL, Chew DP, Hirsch AT, Ringleb PA, Hacke W, Topol EJ. Superiority of clopidogrel versus aspirin in patients with prior cardiac surgery. Circulation. 2001 Jan 23; 103(3):363-8. 477. Chew DP, Bhatt DL, Sapp S, Topol EJ. Increased mortality with oral platelet glycoprotein IIb/IIIa antagonists: a meta-analysis of phase III multicenter randomized trials. Circulation. 2001 Jan 16; 103(2):201-6. 478. Bhatt DL, Topol EJ. Debate: PCI or CABG for multivessel disease? Viewpoint: No clear winner in an unfair fight. Curr Control Trials Cardiovasc Med. 2001; 2(6):260-262. 479. Chew DP, Bhatt DL. Oral glycoprotein IIb/IIIa antagonists in coronary artery disease. Curr Cardiol Rep. 2001 Jan; 3(1):63-71. 480. Chew DP, Bhatt DL, Topol EJ. Oral glycoprotein IIb/IIIa inhibitors: why don't they work? Am J Cardiovasc Drugs. 2001; 1(6):421-8. 481. Marso SP, Bhatt DL, Roe MT, Houghtaling PL, Labinaz M, Kleiman NS, Dyke C, Simmoons ML, Califf RM, Harrington RA, Topol EJ. Enhanced efficacy of eptifibatide administration in patients with acute coronary syndrome requiring in-hospital coronary artery bypass grafting. PURSUIT Investigators. Circulation. 2000 Dec 12; 102(24):2952-8. 482. Bhatt DL, Topol EJ. Current role of platelet glycoprotein IIb/IIIa inhibitors in acute coronary syndromes. JAMA. 2000 Sep 27; 284(12):1549-58. 483. Roe MT, Harrington RA, Prosper DM, Pieper KS, Bhatt DL, Lincoff AM, Simoons ML, Akkerhuis M, Ohman EM, Kitt MM, Vahanian A, Ruzyllo W, Karsch K, Califf RM, Topol EJ. Clinical and therapeutic profile of patients presenting with acute coronary syndromes who do not have significant coronary artery disease.The Platelet Glycoprotein IIb/IIIa in Unstable Angina: Receptor Suppression Using Integrilin Therapy (PURSUIT) Trial Investigators. Circulation. 2000 Sep 5; 102(10):1101-6. 484. Cho L, Marso SP, Bhatt DL, Topol EJ. Optimizing percutaneous coronary revascularization in diabetic women: analysis from the EPISTENT trial. J Womens Health Gend Based Med. 2000 Sep; 9(7):741-6. 485. Bhatt DL, Ellis SG. Is the corrected TIMI frame count an independent predictor of adverse outcome? Circulation. 2000 Jul 11; 102(2):E19. 486. Cura FA, Bhatt DL, Lincoff AM, Kapadia SR, L'Allier PL, Ziada KM, Wolski KE, Moliterno DJ, Brener SJ, Ellis SG, Topol EJ. Pronounced benefit of coronary stenting and adjunctive platelet glycoprotein IIb/IIIa inhibition in complex atherosclerotic lesions. Circulation. 2000 Jul 4; 102(1):28-34. 487. Bhatt DL, Hirsch AT, Ringleb PA, Hacke W, Topol EJ. Reduction in the need for hospitalization for recurrent ischemic events and bleeding with clopidogrel instead of aspirin. CAPRIE investigators. Am Heart J. 2000 Jul; 140(1):67-73. 488. Bhatt DL, Lincoff AM, Califf RM, Simoons ML, Tcheng JE, Brener SJ, Wolski KE, Topol EJ. The benefit of abciximab in percutaneous coronary revascularization is not device-specific. Am J Cardiol. 2000 May 1; 85(9):1060-4. 489. Bhatt DL, Marso SP, Lincoff AM, Wolski KE, Ellis SG, Topol EJ. Abciximab reduces mortality in diabetics following percutaneous coronary intervention. J Am Coll Cardiol. 2000 Mar 15; 35(4):922-8. 490. Bhatt DL, Topol EJ. Percutaneous coronary intervention for patients with prior bypass surgery: therapy in evolution. Am J Med. 2000 Feb; 108(2):176-7. 491. Bhatt DL, Topol EJ. Antiplatelet and anticoagulant therapy in the secondary prevention of ischemic heart disease. Med Clin North Am. 2000 Jan; 84(1):163-79, ix. 492. Bhatt DL, Kapadia SR, Yadav JS, Topol EJ. Update on clinical trials of antiplatelet therapy for cerebrovascular diseases. Cerebrovasc Dis. 2000; 10 Suppl 5:34-40. 493. Marso SP, Lincoff AM, Ellis SG, Bhatt DL, Tanguay JF, Kleiman NS, Hammoud T, Booth JE, Sapp SK, Topol EJ. Optimizing the percutaneous interventional outcomes for patients with diabetes mellitus: results of the EPISTENT (Evaluation of platelet IIb/IIIa inhibitor for stenting trial) diabetic substudy. Circulation. 1999 Dec 21-28; 100(25):2477-84. 494. Bhatt DL, Ellis SG, Ivanc TB, Crowe T, Balazs E, Debowey D, Pangerl A, Chew PH. Corrected TIMI frame count does not predict 30-day adverse outcomes after reperfusion therapy for acute myocardial infarction. Am Heart J. 1999 Oct; 138(4 Pt 1):785-90. 495. Mukherjee D, Bhatt DL, Roe MT, Patel V, Ellis SG. Direct myocardial revascularization and angiogenesis--how many patients might be eligible? Am J Cardiol. 1999 Sep 1; 84(5):598-600, A8. 496. Bhatt DL, Lincoff AM, Kereiakes DJ, Tcheng JE, Simoons ML, van der Wieken LR, Godfrey N, Califf RM, Topol EJ. Reduction in the need for unplanned stenting with the use of platelet glycoprotein IIb/IIIa blockade in percutaneous coronary intervention. Am J Cardiol. 1998 Nov 1; 82(9):1105-6, A6. 497. Bhatt DL, Gaylor DC, Lee RC. Rhabdomyolysis due to pulsed electric fields. Plast Reconstr Surg. 1990 Jul; 86(1):1-11.

Send Feedback to the BWH Biomedical Research Institute.